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Macrophages (MFs) are heterogeneous and metabolically flexible, with metabolism strongly affecting immune activation. A
classic response to proinflammatory activation is increased flux through glycolysis with a downregulation of oxidative metabolism,
whereas alternative activation is primarily oxidative, which begs the question of whether targeting glucose metabolism is a viable
approach to control MF activation. We created a murine model of myeloid-specific glucose transporter GLUT1 (Slc2a1) deletion.
Bone marrow–derived MFs (BMDM) from Slc2a1M2/2 mice failed to uptake glucose and demonstrated reduced glycolysis and
pentose phosphate pathway activity. Activated BMDMs displayed elevated metabolism of oleate and glutamine, yet maximal
respiratory capacity was blunted in MF lacking GLUT1, demonstrating an incomplete metabolic reprogramming. Slc2a1M2/2
BMDMs displayed a mixed inflammatory phenotype with reductions of the classically activated pro- and anti-inflammatory
markers, yet less oxidative stress. Slc2a1M2/2 BMDMs had reduced proinflammatory metabolites, whereas metabolites indicative
of alternative activation—such as ornithine and polyamines—were greatly elevated in the absence of GLUT1. Adipose tissue MFs
of lean Slc2a1M2/2 mice had increased alternative M2-like activation marker mannose receptor CD206, yet lack of GLUT1 was
not a critical mediator in the development of obesity-associated metabolic dysregulation. However, Ldlr2/2 mice lacking myeloid
GLUT1 developed unstable atherosclerotic lesions. Defective phagocytic capacity in Slc2a1M2/2 BMDMs may have contributed to
unstable atheroma formation. Together, our findings suggest that although lack of GLUT1 blunted glycolysis and the pentose
phosphate pathway, MF were metabolically flexible enough that inflammatory cytokine release was not dramatically regulated,
yet phagocytic defects hindered MF function in chronic diseases. The Journal of Immunology, 2019, 202: 1265–1286.
M
acrophages (MFs) are a heterogeneous population
of cells within the innate immune system that play
critical roles in a myriad of processes, including
development, tissue homeostasis, host defense, and tumor growth
(1). MFs exhibit a diverse spectrum of metabolic characteristics
(2–10). In vitro studies have informed early findings that classically
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activated (“M1”-like) MFs use primarily glycolysis, which is
linked to the proinflammatory phenotype characterized by the
production of high levels of proinflammatory cytokines and reactive
oxygen and nitrogen metabolites plus microbicidal and phagocytic
properties (11–13). In contrast, alternatively activated (“M2”-like)
MFs predominantly rely on mitochondrial oxidative metabolism
(13–20), with a lesser dependence on glycolysis (21–24). Alterna-
tive M2-like MFs are associated with tissue homeostasis and res-
olution of the inflammatory response. Yet recent in vivo and in vitro
studies underscore that classical and alternative phenotypes are not
dichotomous but overlap (25, 26). Importantly, immunometabolism
has emerged as a critical driver of MF activation and phenotype
(26); however, minimal research has been conducted to understand
how the metabolic phenotype of MFs influences disease progres-
sion (3, 27). Thus, a better understanding of MF metabolism may
shed an innovative light on the pathological basis of disease
and lead to the future development of MF-targeted treatment
approaches.
We have previously reported that the glucose transporter GLUT1
(encoded by Slc2a1) is a critical modulator of MF glucose meta-
bolism and inflammation (11). Overexpression of GLUT1 in MFs
significantly increased glucose uptake, glycolysis, and the expres-
sion of proinflammatory cytokines associated with systemic meta-
bolic dysfunction (e.g., TNF-a, IL-1b, and IL-6) even in the
absence of activating stimuli. Expression of plasminogen activator
inhibitor-1 (PAI-1), a GLUT1-dependent cytokine associated with
metabolic disease, was also increased in a glycolysis- and reactive
oxygen species (ROS)–dependent manner (11, 27). Furthermore,
GLUT1 expression was identified in adipose tissue crown-like
structures (CLS), aggregates of immune cells surrounding dead or
dying adipocytes that are increased in adipose tissue of obese mice
and humans (11). Flow cytometric analysis revealed that adipose
tissue MFs that highly expressed GLUT1 also had greater TNF-a
expression (11). Taken together, these results implicated GLUT1 as
a critical modulator of MF metabolism and inflammatory capacity,
suggesting that GLUT1 or glycolysis could be an attractive target to
limit inflammation, but loss of function studies were lacking.
Because GLUT1 is the primary receptor for glucose uptake in
MFs (11), we hypothesized that restricting glucose uptake through
GLUT1 ablation could impact metabolic and immunoregulatory
pathways. In this article, we report that bone marrow–derived MFs
(BMDMs) lacking GLUT1 (Slc2a1M2/2) demonstrated a reduced
inflammatory phenotype with evidence of substrate switch, resort-
ing to elevated fatty acid and glutamine metabolism in the absence
of GLUT1-mediated glycolysis and pentose phosphate pathway
(PPP). In addition, Slc2a1M2/2 BMDMs displayed reduced oxida-
tive stress and increased capacity to buffer from oxidative insult.
Taken together, the absence of GLUT1 limited overall activation
with a potentially more alternatively activated phenotype. Because
of this complex phenotype, we hypothesized that the absence of
GLUT1-mediated metabolism in MFs may protect against patho-
genic sequelae of diseases associated with MF inflammation.
We next examined the effects of myeloid-specific Slc2a1 deletion
in two models of MF-associated disease: diet-induced obesity and
atherosclerosis. As adipose tissue expands in obesity, MF content
increases considerably, where they play a role in cell turnover, lipid
trafficking, and inflammation and subsequent metabolic dysfunction
(9, 20, 28–31). Thus, we hypothesized that deleting GLUT1 in MFs
would reduce obesity-associated adipose tissue inflammation and
thereby modulate the onset of metabolic dysfunction. Unexpectedly,
in adipose tissue of obese Slc2a1M2/2 animals, we observed an
elevation in markers of MF infiltration and increased expression of
proinflammatory mediators such as MCP-1 (Ccl2) compared with
obese control mice. However, despite increased MF infiltration in
obese Slc2a1M2/2 adipose tissue, there were no differences in
glucose or insulin tolerance between Slc2a1M2/2 mice and obese
floxed littermate controls, measures typically associated with MF
markers, thus indicating that increased MF infiltration failed to elicit
a commensurate increase in the typical proinflammatory response in
the absence of GLUT1. Interestingly, in older mice, flow cytometric
analysis of adipose tissue MFs from lean Slc2a1M2/2 mice revealed
increased expression of mannose receptor CD206, an alternative M2-
like marker. Thus, despite skewing of the MF phenotype toward the
alternative phenotype, deficiency of myeloid GLUT1 surprisingly did
not alter diet-induced obesity-associated systemic pathological con-
ditions. MFs also play a critical role in the pathogenesis of athero-
sclerosis through clearance of modified low-density lipoprotein
(LDL) particles, efferocytosis, and control of the immune milieu
(32, 33). Therefore, we next determined whether lack of GLUT1-
mediated glucose metabolism in MFs would reduce the extent of
atherogenesis. In Slc2a1M2/2 bone marrow–recipient Ldlr2/2 mice
(Slc2a1M2/2 Ldlr2/2), a greater percentage of mice suffered from
large, necrotic, and unstable lesions compared with Slc2a1fl/fl re-
cipient mice (Slc2a1fl/fl Ldlr2/2), despite a lack of major systemic
alterations. Interestingly, further analyses demonstrated signifi-
cantly impaired phagocytic capacity in Slc2a1M2/2 MFs, which
may have contributed to defective tissue homeostasis in lesions.
Together, these studies illuminate a critical role for myeloid-
specific GLUT1-mediated glucose metabolism in directing in-
flammatory potential of MFs.
Materials and Methods
Reagents
All reagents were obtained from Sigma-Aldrich (St. Louis, MO) unless
otherwise noted. IFN-g and IL-4 were obtained from R&D Systems
(Minneapolis, MN). M-CSF was obtained from BioLegend (San Diego,
CA). LPS (E. coli L4391; Sigma-Aldrich) was diluted in sterile PBS at a
final concentration of 1 mg/ml. Novolin human insulin was purchased
from Novo Nordisk (Plainsboro, NJ). Glucometer and glucose strips were
purchased from Abbott Diabetes Care (Abbott Park, IL). FBS, RPMI 1640,
1003 L-glutamine, and 1003 penicillin/streptomycin antibiotic mix were
obtained from CellGro (Corning, NY). Abs were purchased from the fol-
lowing sources: anti-F4/80 (MCA497) and MF/monocyte mAb (MOMA2)
(MCA519G) (AbD Serotec/Bio-Rad, Hercules, CA), anti-GLUT1 (ab40084;
Abcam, Cambridge, MA), anti-actin (MAB1501) (EMD Millipore, Billerica,
MA), and Annexin VApoptosis Detection Kit PE (Thermo Fisher Scientific,
Waltham, MA); mouse IgG (Thermo Fisher Scientific); goat anti-mouse IgG,
Rhodamine Red conjugate (Thermo Fisher Scientific); goat anti-mouse
IgG Cy5 (Thermo Fisher Scientific); and Alexa Fluor 488 Phalloidin
(Thermo Fisher Scientific) or peroxidase-conjugated goat anti-mouse
secondary Ab (NXA931; GE Healthcare Life Science, Piscataway, NJ).
Fluoro-Gel II with DAPI was purchased from Electron Microscopy
Sciences (Hatfield, PA). Carboxylate microspheres were obtained from
Polysciences (Warrington, PA).
Animals and maintenance
Animal studies were performed with approval and in accordance with the
guidelines of the Institutional Animal Care and Use Committee at the
University of North Carolina (UNC) at Chapel Hill and University of Ten-
nessee Health Science Center. All animals were housed in a temperature-
controlled facility with a 12-h light/dark cycle and ad libitium access to food
and water. B6.129P2-Lyz2tCAM(cre)Ifo/J (LysMCre) mice (stock number:
004781), Ldlr2/2mice (stock number: 002207), and C57BL/6J mice (stock
number: 000664) were purchased from The Jackson Laboratory (Bar Harbor,
ME). Floxed Glut1 mice on a C57BL/6J background were a kind gift from
E.D. Abel (34) (University of Iowa). For experiments, control mice had
two floxed Glut1 alleles and no LysMCre alleles (Slc2a1fl/fl), whereas
myeloid-specific Slc2a1 knockouts harbored two floxed alleles and one
LysMCre allele (Slc2a1M2/2) as shown in Fig. 1A.
DNA isolation and genotyping
Genomic DNA was isolated from tail biopsies using a DNeasy Blood and
Tissue Kit (Qiagen, Valencia, CA). Genotyping for LysMCre is detailed on
Seahorse Bioscience (Billerica, MA) 96-well plate in RPMI 1640 sup-
plemented with 20 ng/ml M-CSF and incubated overnight at 37˚C in
an atmosphere of 5% CO2. Cells were left unstimulated or LPS/IFN-g– or
IL-4–stimulated for 24 h. Glycolysis stress test assay medium included
XF Base Media (DMEM) purchased from Seahorse with 2 mM glutamine
supplemented. Glucose was injected to a final concentration (FC) of
10.0 mM, oligomycin to an FC of 1.0 mM, and 2-deoxyglucose (2-DG) to
an FC of 50 mM. For the mitochondrial stress test, medium included
XF Base Media (DMEM) with 10 mM glucose, 2 mM glutamine, and
1 mM sodium pyruvate supplemented. In the mitochondrial stress test, oli-
gomycin was injected to an FC of 1.0 mM, FCCP to an FC of 1.5 mM, and
rotenone/antimycin A (Sigma-Aldrich) to an FC of 0.50 mM. All reagents
were sterile, and all experimental media were freshly prepared and at a pH of
7.4 before each assay. Live and dead cell analysis using calcein AM and
EthD-1, respectively, did not reveal any change in death or number of live
cells by treatment or genotype (Molecular Probes, Eugene, OR, data not
shown). Bioenergetics were determined by recording extracellular acidifi-
cation rates (ECAR; milli-pH units per minute) and oxygen consumption
rates (OCR; picomol of O2 per minute). All rates were normalized to DNA
content using CyQUANT Cell Proliferation Assay Kit (Molecular Probes)
and quantified on CLARIOstar BMG Lab Tech (Cary, NC).
[13C]-glutamine enrichment, extraction, and liquid
chromatography–mass spectrometry analysis
BMDMwere differentiated from bone marrow of age-matched 10-wk-old
male control and Slc2a1M2/2 littermates and plated onto six-well plates.
The next day, cells were stimulated with LPS/IFN-g for 24 h as described
above. Cells were plated with unlabeled 4 mM [12C]-glutamine growth
media (n = 2 per genotype) and were used to calculate natural abundance
(background) of each metabolite measured. For experimental cells,
[12C]-glutamine was replaced with sterile 4 mM [U-13C]-glutamine
(Isotec/Millipore) in the same conditions, except for phenol red–free
RPMI for the last 16 h of LPS/IFN-g stimulation. Media was removed
from cells, and 1 ml of ice-cold 80% methanol was added to each well on
dry ice. Plates were placed in 280˚C for 15 min to inactivate enzymatic
activity. Scraped lysates were collected into Eppendorf tubes and dried in
a vacuum concentrator at room temperature. Metabolite extraction was
performed as described in our previous study (39). The dry pellets were
reconstituted into 30 ml of sample solvent (water/methanol/acetonitrile,
2:1:1, v/v), and 3 ml was analyzed by liquid chromatography–mass
spectrometry for mass isotopomer distribution (MID) of each metabolite.
Ultimate 3000 UHPLC (Dionex) was coupled to Q Exactive Plus-Mass
spectrometer (Thermo Scientific) for metabolite profiling. A hydrophilic
interaction chromatography method employing an Xbridge amide col-
umn (100 3 2.1 mm inner diameter, 3.5 mm; Waters) is used for polar
metabolite separation. A detailed liquid chromatography method was
described previously (40), except that mobile phase A was replaced with
water containing 5 mM ammonium acetate (pH 6.8). The Q Exactive
Plus-Mass spectrometer is equipped with a HESI Probe with related
parameters set as below: heater temperature, 120˚C; sheath gas, 30;
auxiliary gas, 10; sweep gas, 3; spray voltage, 3.0 kV for the positive
mode and 2.5 kV for the negative mode; capillary temperature, 320˚C;
S-lens, 55; and a mass to charge ratio of 70 to 900 was used in positive
mode from 1.31 to 12.5 min. For negative mode, the parameters were
as follows: a scan range of 70–900 was used from 1.31 to 6.6 min and
then 100 to 1000 was used from 6.61 to 12.5 min; resolution: 70,000;
and automated gain control, 3 3 106 ions. Customized mass calibration
was performed before data acquisition. Liquid chromatography–mass
spectrometry peak extraction and integration were performed using
commercially available software Sieve 2.2 (Thermo Fisher Scientific).
The peak area was used to represent the relative abundance of each
metabolite in different samples. The missing values were handled as
described in our previous study (40). The fractional contribution of
[13C]-glutamine to each of the metabolite pools was determined from the
molar percent enrichments as calculated from the MIDs after correction
for natural abundance. Two-way ANOVA with Tukey correction was
used to test for genotype effect in each isotope.
Quantitative RT-PCR analysis
mRNA was isolated using Qiagen’s RNeasy mini kit. The RNA quantity
and quality were determined using Nanodrop (Thermo Fisher Scientific)
and reverse transcribed into cDNA using the iScript cDNA synthesis kit
(Bio-Rad). The expression of specific genes was quantitated by quantita-
tive PCR (qPCR) using Assay-On-Demand (Thermo Fisher Scientific) or
Roche’s Universal ProbeLibrary (Indianapolis, IN) on an ABI 7900HT
machine (Thermo Fisher Scientific) as in Qin et al. (41). Expression
levels of genes of interest were normalized to expression of the rRNA
The Jackson Laboratory’s Web site (http://jaxmice.jax.org). Genotyping 
for Glut1 was performed using the following primers: flanked loxP 
forward – 59-CTGTGAGTTCCTGAGACCCTG-39; flanked loxP reverse – 59-
CCCAGGCAAGGAAGTAGTTC-39. The primers flank the upstream LoxP 
site located upstream of exon 3. The resulting PCR products are either only 
wild-type DNA (product 350 bp) or wild-type DNA with the upstream LoxP 
site included (floxed product 500 bp). The following amplification scheme 
was used: 98˚C for 1 min for 1 cycle; 98˚C for 10 s, 58˚C for 10 s, 98˚C for 
25 s for 40 cycles; and then 4˚C to soak. iProof High-Fidelity PCR supermix 
(Bio-Rad)–based genotyping was performed on a C1000 Touch Thermal 
Cycler (Bio-Rad).
Hematologic analysis
Hematologic analysis was conducted on fed 8-wk-old Slc2a1fl/fl and Slc2a1M2/2 
age-matched male mice maintained on ad libitum chow. Flow cytometry was 
used to enumerate circulating leukocyte populations. Blood was collected, and 
RBCs were lysed in ACK lysis buffer. Cells were washed twice in HBSS, 
resuspended in PBS, counted, and then 1 3 105 cells were stained with CD45-
FITC, F4/80-PE, Ly6G/C-PE-Cy7, CD11b-allophycocyanin, and CD11c-
allophycocyanin-eFluor 780 in the presence of anti-CD16/32 (Fc block) in 
FACS buffer (1% FBS in PBS) as described by Johnson et al. (20). Samples 
were analyzed on the Dako CyAn ADP flow cytometer (Beckman Coulter, 
Fullerton, CA) and FlowJo Software (TreeStar, Ashland, OR).
Cell culture and primary cell isolation
To generate BMDM, bone marrow was harvested from age-matched male 
Slc2a1fl/fl and Slc2a1M2/2 as previously described (20). BMDMs were 
generated by culturing marrow cells in 10-cm non–tissue culture–treated 
dishes for 6 d with 20 ng/ml M-CSF or 30% L929 conditioned media 
supplemented as indicated, in RPMI 1640 supplemented with 10% FBS, 
13 L-glutamine, and 13 penicillin/streptomycin antibiotic mix. BMDMs 
were left untreated as naive, unstimulated MФs or activated using 5 ng/ml 
LPS and 10 ng/ml IFN-g (M1-like) or 10 ng/ml IL-4 (M2-like) for 24 h 
(11, 13, 20). Cell densities and viability were determined by hematocy-
tometer and trypan blue exclusion, respectively. Cell size, volume, and 
viability were determined using a Sceptor handheld automated cell counter 
(Millipore). To isolate peritoneal MFs, mice were injected i.p. with 1 ml of 
sterile 4% thioglycollate. Four days later, thioglycollate-elicited peritoneal 
MFs were obtained as described (35). All cultures were maintained under 
a fully humidified atmosphere of 95% air and 5% CO2 at 37˚C.
Substrate metabolism and metabolomics
Slc2a1fl/fl versus Slc2a1M2/2 BMDMs were plated at 4.0 3 105 cells per 
well into 24-well plates and allowed to attach overnight. Cells were acti-
vated as described above, and uptake and metabolism of substrates were 
measured as in Freemerman et al. (11). Briefly, [3H]-glucose uptake was 
measured for 10 min at 37˚C in 0.5 ml/well KRH buffer (136 mM NaCl, 
4.7 mM KCl, 1.25 mM CaCl2, 1.25 mM MgSO4, 10 mM HEPES [pH 7.4]) 
with 0.5 mCi/ml [3H]2-Deoxy-D-glucose (PerkinElmer, Waltham, MA). 
Glucose oxidation to CO2 was measured by incubating cells with ubiq-
uitously labeled [14C]-glucose for 2 h and then measuring [14C]-CO2 in the 
media (36). Oleate oxidation to CO2 was measured by incubating cells 
with 1-[14C]-oleate for 2 h and measuring [14C]-CO2 in the media. Protein 
concentrations were determined with a BCA assay (Thermo Fisher Sci-
entific). BODIPY-palmitate uptake was measured by flow cytometry to 
quantitate fatty acid uptake. For targeted metabolomics analysis, Slc2a1fl/fl 
or Slc2a1M2/2 were plated on 10-cm non–tissue culture–treated dishes at 
5 3 105 cells/ml and allowed to attach overnight. Fresh media was added, 
and cells were left as unstimulated or LPS/IFN-g–activated for 24 h. PBS-
washed cells were detached by trypsin and pelleted for analysis by 
Metabolon (Durham, NC) (11, 37), with n = 4 replicates per group. Data 
are presented as relative measures of “scaled intensity” after normalization 
to protein and median scaling to 1. Missing values were imputed with the 
minimum. The principal component analysis plot was constructed using 
ArrayStudio V5.0 (OmicSoft, Cary, NC).
Cellular bioenergetics analyses
Metabolic phenotyping assays were conducted on Slc2a1fl/fl versus 
Slc2a1M2/2 BMDMs (11, 38). Seahorse glycolysis and mitochondrial 
stress tests were conducted on the Seahorse Bioscience XF96 Extracellular 
Flux Analyzer (Billerica, MA) after optimization. Four doses of cell 
densities, concentrations of FCCP, and concentrations of oligomycin were 
tested in both stress tests for the best metabolic performance of BMDMs. 
For all assays, 50,000 BMDMs was determined to be the best concentra-
tion along with 1.5 mM FCCP or 1 mM oligo. BMDMs were seeded in a
18S. Animals whose body weight was at or above the mean body weight
for the high-fat diet (HFD) and low-fat diet (LFD) experimental groups
were selected for analysis; therefore, unless indicated, n = 8–9 per group
for mouse data and n = 3–6 experiments for BMDM studies. Data are
presented as ΔΔCt calculations normalized to the baseline value.
Microarray analysis
RNA sample quality was assessed using the RNA ScreenTape assay (Agilent,
Santa Clara, CA). Samples (2 ml) were Cy3-labeled with the Agilent Low-
Input Quick Amp Labeling Kit and hybridized to SurePrint G3 Mouse GE
8 3 60K microarrays (Agilent). Four biological replicates for each of three
BMDM activation states (unstimulated, LPS/IFN-g, and IL4) from both
Slc2a1M2/2 and Slc2a1fl/fl mice were measured (National Center for Bio-
technology Information Gene Expression Omnibus upload; accession
number: GSE123289; https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE123289). Hierarchical gene clustering was conducted using the
average linkage clustering algorithm in Cluster 3.0 (Stanford, CA). Two-
class unpaired significance of microarray analyses were then performed.
Normalized data from Slc2a1M2/2 BMDMs were log transformed using
Cluster 3.0, and genes were again clustered hierarchically using an average
linkage algorithm. Heat maps were generated using Java TreeView. Data
are presented as the log2-based fold change of each gene in individual
Slc2a1M2/2 samples relative to the average expression of that gene across all
four Slc2a1fl/fl samples. Ingenuity Pathway Analysis (Redwood City, CA)
was used to identify significant functions and pathways (p , 0.05 with
Benjamini–Hochberg correction for multiple comparisons testing). Metab-
oanalyst was used to integrate metabolite and gene expression data for
pathway analysis, according to default parameters.
Protein expression analysis
Cells were lysed in radioimmunoprecipitation assay buffer (50 mM Tris,
150mMNaCl, 0.1% SDS, 0.5%deoxycholate, 1%TX-100) with 13 protease
and phosphatase inhibitors (Sigma-Aldrich). Protein concentration was de-
termined using the BCA assay (Thermo Fisher Scientific). Anti-GLUT1
primary Ab, anti-actin Ab, or peroxidase-conjugated goat anti-mouse
secondary Ab (NXA931; GE Healthcare Life Science, Piscataway, NJ)
were used and developed by chemiluminescence (Amersham ECL Se-
lect; GE Healthcare Life Science) and quantitated using a VersaDoc 4000
instrument and software (Bio-Rad) or Li-Cor Odyssey (Lincoln, NE).
Blots were quantitated from three separate experiments. All lanes were
normalized to b-actin for loading. Concentrations of IL-6, TNF-a, IL1b,
IL-10, and MCP-1 in conditioned media were measured using a
MAGPIX Luminex kit (EMD Millipore).
Atherosclerosis study: bone marrow transplantation and
metabolic parameters
The atherosclerosis study was conducted as previously described (42).
Briefly, at 6 wk of age, Ldlr2/2 mice received two doses of x-ray radiation
(500 cGy 3 2, spaced 4 h apart; X-RAD, North Branford, CT) and were
then transplanted with bone marrows isolated from Slc2a1 fl/fl or Slc2a1M2/2
donor mice. Control animals were transplanted with the HBSS buffer only
and died within 10–11 d of lethal irradiation. Following bone marrow
transplant (BMT) (43), chimeric Ldlr2/2 mice were transferred to sterile
cages with ad libitium access to sterile mouse chow and sterile water and
were maintained on a chow diet for 4 wk before challenge with Western diet
(TD88137, 42% of Kcal from milk fat with 0.15% added cholesterol) from
Harlan Teklad (Indianapolis, IN) for 12 wk. Body weight and body com-
position was measured (by magnetic resonance imaging [MRI]) across the
study. Fasting plasma lipids were measured in the UNC Animal Clinical
Chemistry and Gene Expression Core Facility. Blood pressure was measured
using a tail-cuff system in UNC Rodent Advanced Surgical Models Core
Lab of the UNC McAllister Heart Institute. Mice (n = 8) received five
consecutive days of training on the tail-cuff blood pressure system (CODA;
Kent Scientific, CA) prior to data collection. Starting on day 6, systolic and
diastolic blood pressure was measured in conscious mice daily for 3 d. Mice
were acclimated to the warm (32˚C) restrainer for 15 min and blood pressure
was recorded during 10 acclimations followed by 25 measurement cycles.
Aortic histology and immunohistochemistry quantification
Mice dissections were done as previously described (42). Briefly, following
dissection, hearts were either transferred to 70% ethanol and stored at 4˚C for
future creation of formalin-fixed, paraffin-embedded sections or transferred
to 30% sterile sucrose for 72 h for generating cryosectioning slides. For-
malin-fixed, paraffin-embedded sections were stained with Masson’s tri-
chrome for quantification of collagen content, necrotic core areas, and
subendothelium cell numbers, and with anti-MOMA2 for MFs. Frozen
sections were stained with Oil Red O (ORO) for quantification of lesion
area. A color deconvolution algorithm, developed by UNC Translational
Pathology Laboratory, was used for digital quantification of collagen,
reported as OD 3 percent of total positive area stained with collagen
(44–46). Necrotic core size and subendothelial cell nuclei were quantified
on Masson’s trichrome–stained slides, which were normalized to the total
quantified area. Necrotic core size was measured using Aperio ePathology
software (Aperio, Buffalo Grove, IL), and subendothelial cell numbers
were assessed manually by counting nuclei. Quantification of MFs was
calculated as OD 3 percent of total positive area stained with anti-
MOMA2. Quantification of atherosclerotic lesions was done as described
with modification (47, 48).
Obesity study: metabolic phenotyping
Mice were weaned onto and given ad libitum access to either a purified diet
containing 10% kCal from fat (LFD; D12450B; Research Diets, New
Brunswick, NJ) or a diet containing 45% kCal from fat (HFD; D12451;
Research Diets) for 23 wk (n = 14–19 mice per diet per genotype). Body
weight was measured prior to starting mice on LFD or HFD at weaning
and weekly thereafter. Body composition was measured at 4, 8, and 20 wk
using the EchoMRI-100 quantitative magnetic resonance whole body
composition analyzer (EchoMRI Medical Systems, Houston, TX). Blood
glucose was measured at 3 wk on the diets and again at termination, both
following a 6-h fast. i.p. glucose tolerance tests and insulin tolerance tests
were performed at weeks 21 and 22 on diet, following 6- or 4-h fast, re-
spectively (42). Briefly, 2.0 gm/kg body weight of glucose or 0.75 U of
insulin was injected i.p., and blood glucose was measured over 120 min.
Plasma insulin was measured by ELISA (EMD Millipore). Energy ex-
penditure was evaluated in TSE Systems cages over 48 h on a subgroup of
mice at 23 wk (n = 3–5 per group).
Epididymal white adipose tissue and blood collection
For tissue collection, bloodwas collected via cardiac puncture from anesthetized
mice. Plasma was separated from other blood components by centrifugation
at 200 3 g for 5 min at 4˚C. Epididymal white adipose tissue (eWAT)
was collected and fixed in 10% formalin for histological analyses. A
portion of each tissue was flash frozen in liquid nitrogen. Anti-F4/80
immunohistochemical staining was conducted, as previously described
(46). All histological sections were analyzed using ScanScope Image
Analysis Toolbox software (Buffalo Grove, IL) (46). CLS were quanti-
tated under original magnification 320 by counting six identically sized
boxed areas (fields) placed randomly over the scanned area of interest.
CLS are presented as CLS per field.
Flow cytometric analysis of epididymal white adipose MFs
Male Slc2a1fl/fl and Slc2a1M2/2 mice (n = 4 per diet and genotype) were
weaned onto a LFD or HFD at 3 wk of age and maintained on diets for an
average of 46.14 wk. Mice were anesthetized by i.p. injection of
2,2,2-tribromoethanol in tertiary amyl alcohol (250 mg/kg), followed by
exsanguination via cardiac puncture and subsequent cervical dislocation.
The peri-epididymal adipose pad from each mouse was excised and trans-
ferred to ice-cold high-glucose DMEM (Corning, Corning, NY) containing
20 mM HEPES buffer (Cellgro, Manassas, VA), 10% bovine calf serum
(Hyclone, GE Healthcare Life Sciences, South Logan, UT), 10% glutamine,
and 10% penicillin-streptomycin. Individual adipose pads were weighed,
imaged, and minced with surgical scissors. A single-cell suspension was
generated by digestion in 2 mg/ml type I collagenase (Worthington, Lake-
wood, NJ) at 37˚C followed by gentle mechanical dissociation using a
Stomacher 80 Biomaster small tissue laboratory paddle blender (Seward,
Worthing, West Sussex, U.K.). An immune cell–enriched stromal-vascular
fraction (SVF) was obtained by dilution with an equal volume of HEPES-
buffered DMEM, filtration through a 100-mm cell strainer, and centrifugation
at 200 3 g for 10 min at 4˚C. The resulting SVF pellet was incubated in
ACK lysis buffer (Life Technologies, Gaithersburg, MD) for 3–5 min at
room temperature to lyse RBCs and then washed in HEPES-buffered
DMEM. A 10-ml aliquot of cell suspension was diluted 1:2 with trypan
blue, followed by analysis of live cells using a Bio-Rad TC 20 automated
cell counter to determine total SVF cells obtained from adipose pads of
individual mice. Two million SVF cells per mouse were transferred to a 96-
well plate, blocked, and stained with pretitrated Abs. Abs or stains were used
as follows: 1) Fc block (CD16/32) at 1:50 (no. 101320, lot B200134; Bio-
Legend), 2) live/dead (Zombie Green) at 1:400 (no. 423111; BioLegend), 3)
CD45 (BV605) at 1:200 (no. 103140, lot B211813; BioLegend), 4) CD11b
(BUV395) at 1:100 (no. 563553, lot 6028814; BD Biosciences), 5) CD64
(PE-Cy7) at 1:200 (no. 139313, lot B197402; BioLegend), and 6) CD206
(BV785) at 1:100 (no. 141729, lot B229782; BioLegend). The remaining
treated with 5 ng/ml LPS and 10 ng/ml IFN-g or 10 ng/ml IL-4 for
24 h to model classical/M1-like or alternative/M2 activation, re-
spectively (11, 13). Lack of Slc2a1 mRNA and GLUT1 protein was
confirmed in unstimulated, LPS/IFN-g–, and IL4-activated BMDMs,
indicating successful ablation through LysMCre recombinase activity
(Fig. 1B, 1C, p , 0.0001 Slc2a1fl/fl versus Slc2a1M2/2). We next
determined the dependence of MF metabolic phenotype upon
GLUT1-mediated glucose transport by assessing glucose uptake,
glucose oxidation, fatty acid uptake, and fatty acid oxidation. Uptake
of 3H–2-DG in control Slc2a1fl/fl LPS/IFN-g–activated BMDMs was
significantly increased by 26-fold relative to unstimulated Slc2a1fl/fl
BMDMs (Fig. 1D, p, 0.0001 control cells, black bars, unstimulated
versus LPS/IFN-g) (11). However, in the absence of GLUT1,
2-DG uptake was essentially abolished in Slc2a1M2/2BMDMs
in both unstimulated and IL4-stimulated MFs, whereas glucose
uptake was dramatically reduced in Slc2a1M2/2LPS/IFN-g–
stimulated MFs compared with Slc2a1fl/fl controls (Fig. 1D,
p , 0.0001 Slc2a1fl/fl versus Slc2a1M2/2). The slight increase
in glucose uptake in LPS/IFN-g–stimulated MFs may be due to
contaminating cells in the BMDM preparation. We deter-
mined that preparations were 97.7% MFs (data not shown).
Indeed, in a more pure population of MFs, glucose uptake was
similarly ablated in Slc2a1M2/2 thioglycollate-elicited peritoneal
MFs compared with Slc2a1fl/fl controls, both at baseline and fol-
lowing stimulation with LPS (Fig. 1E, p , 0.0001 Slc2a1fl/fl versus
Slc2a1M2/2). Radiotracer studies demonstrated that glucose oxi-
dation was increased in floxed controls in LPS/IFN-g–activated
BMDM by 1.7-fold, likely because of the increased glucose flux
through the PPP and tricarboxylic acid cycle associated with
proinflammatory activation (Fig. 1F). However, glucose oxidation
was decreased by 65–90% in Slc2a1M2/2BMDMs in the unsti-
mulated, LPS/IFN-g, and IL4 treatments compared with Slc2a1fl/fl
BMDMs (Fig. 1F; p , 0.0001 Slc2a1fl/fl versus Slc2a1M2/2). To
determine if the absence of GLUT1-mediated glucose entry also
altered fatty acid use, we used fluorescent and radiotracer stud-
ies to measure fatty acid uptake and oxidation, respectively. Fatty
acid uptake was increased ∼20–50% in unstimulated and LPS/
IFN-g–treated Slc2a1M2/2 BMDMs compared with controls
(Fig. 1G, p , 0.05 in unstimulated and p , 0.001 in LPS/IFN-g
treatments, Slc2a1fl/fl versus Slc2a1M2/2). As we have previously
observed (11), oleate oxidation was greatly reduced in LPS/IFN-g–
stimulated Slc2a1fl/l BMDMs compared with unstimulated and
IL4-stimulated BMDM. However, oleate oxidation was increased
by Slc2a1 deficiency in both unstimulated (p , 0.01) and
IL4-activated BMDMs (p , 0.0001) (Fig. 1H, Slc2a1fl/fl versus
Slc2a1M2/2). In summary, MFs lacking GLUT1 displayed se-
verely impaired glucose use and increased reliance upon alternate
substrates, such as fatty acids. Remarkably, despite the absence of
GLUT1, no compensatory upregulation of glucose transporter
function was detected.
Slc2a1 deficiency impaired activation-associated metabolic
reprogramming of MFs
To further investigate the metabolic impact of GLUT1 depletion,
we next measured substrate metabolism and mitochondrial ca-
pacity in Slc2a1fl/fl versus Slc2a1M2/2 BMDMs using the Seahorse
bioanalyzer. Glycolysis stress tests demonstrated that control
BMDMs behaved as expected, with the greatest glycolysis, gly-
colytic capacity, and glycolytic reserve in LPS/IFN-g–stimulated
cells (Fig. 2). Following glucose injection, a large increase in
glycolysis was detected, which increased to the highest rates after
oligomycin inhibition of ATP synthase (i.e., respiration) as we
have observed previously (11). Unstimulated and IL-4–polarized
floxed control BMDMs displayed lower rates of glycolysis
SVF cells from each adipose pad were pooled for single-color and 
fluorescence-minus-one controls. Live–dead discrimination was conducted 
using Zombie Green fixable viability dye (BioLegend), according to man-
ufacturer instructions. Abs for extracellular Ag staining were diluted in 
Dulbecco’s PBS containing 2% FBS and 5 mM EDTA. SVF cells were 
then washed twice, fixed/permeabilized using Cytofix/Cytoperm Fixation/
Permeabilization solution (BD Biosciences, San Jose, CA), and resus-
pended in Dulbecco’s PBS containing 2% FBS and 5 mM EDTA. Following 
filtration through a 30-mm filter, SVF cells were analyzed on a BD LSR II 
flow cytometer. Compensation was set using single-stained cellular controls, 
and gating was determined based on fluorescence-minus-one controls. Data 
were analyzed with FlowJo software, version 10 (FlowJo, Ashland, OR).
Microsphere engulfment phagocytic assay
Using carboxylate microspheres, phagocytic capacity in thioglycollate-
elicited peritoneal MFs was measured ex vivo (42, 49). Briefly, 
thioglycollate-elicited peritoneal MFs were seeded on collagen-coated 
Nunc Lab-Tek Chamber Slides (Sigma-Aldrich) overnight. The next day, 
carboxylated microspheres were incubated with MFs for either 20 or 60 
min at 37˚C. Goat anti-mouse Rhodamine Red-X (Life Technologies, CA) 
was first incubated with cells for 15 min. Cells were then permeabilized. 
Goat anti-mouse Cy5 and Alexa 488-Phalloidin (Life Technologies) were 
then incubated with cells for another 30 min. Cells were then mounted 
with fluorescent mounting media. A ZEISS LSM 700 confocal microscope 
was used to capture the images (UNC Microscopy Core). Phagocytosis 
index was calculated by numbers of microspheres adherent to or engulfed 
by cells, respectively, divided by total nuclei in the field and reported as 
beads per cell. Experiments were repeated three times, with four technical 
replicates per genotype per experiment, and two fields per well from each 
experiment were captured for analysis.
ROS production
Slc2a1fl/fl or Slc2a1M2/2BMDMs were either untreated or stimulated with 
LPS 100 ng/ml for 4 h. Cells were incubated with dihydroxyrhodamine 
(DHR-1,2,3; Sigma-Aldrich) for 20 min and then trypsinized for flow 
cytometric analysis. Total ROS was quantified using a Beckman Coulter 
CyAn ADP flow cytometer (Brea, CA). Flow cytometry data were ana-
lyzed using FlowJo software (TreeStar), and median fluorescence intensity 
(MFI) was quantified in at least 5 3 103 cellular events.
Statistics
For all in vivo and ex vivo data, statistical differences between experimental 
groups were determined by two-way ANOVA, and Tukey correction for 
multiple comparisons were performed using statistical software within 
GraphPad Prism, as indicated (GraphPad Software, La Jolla, CA). For body 
weight data, to account for the repeated measures over time within animals, 
an autoregressive within-subject correlation matrix was fit. F-tests using 
the resulting parameter and SE estimates were constructed to make com-
parisons of interest. Analyses were performed using SAS Version 9.3 
(SAS Institute, Cary, NC). All experiments were repeated three or more 
times in triplicate, unless otherwise indicated. Data are shown as mean 6 
SEM. The p values , 0.05 were considered statistically significant.
Results
Lack of GLUT1 impaired glucose uptake and oxidation,
leading to a substrate switch in MFs
As shown in Fig. 1A, Slc2a1fl/fl/LysMCre+/2 mice were bred to
generate male Slc2a1M2/2 mice (two floxed Slc2a1 alleles and two
LysMCre alleles) and littermate Slc2a1fl/fl controls (two floxed Slc2a1
alleles and no LysMCre alleles). We first investigated whether Slc2a1
deletion reduced the number of circulating myeloid cells, such as
neutrophils and cells of the monocyte-MF lineage. Using flow
cytometry, hematologic analyses did not show any significant dif-
ferences in circulating myeloid cells in Slc2a1M2/2 mice compared
with Slc2a1fl/fl mice, confirming that Slc2a1 deletion did not impair
differentiation of select myeloid lineages or their egress from bone
marrow [data not shown; gating strategy is the same as our previous
work (20)]. Differentiated BMDMs from Slc2a1M2/2 mice were vi-
able with no apparent morphological differences from Slc2a1fl/fl
BMDMs (data not shown). To determine the impact of Slc2a1 de-
letion on MF activation, BMDMs were either left unstimulated or
compared with M1-like LPS/IFN-g activation, as expected. The
lack of GLUT1 resulted in a reduced ECAR in Slc2a1M2/2 rel-
ative to Slc2a1fl/fl control BMDMs over the time course (Fig. 2A).
In the basal state (from 0 to 20 min), the absence of GLUT1 re-
duced the ECAR only in LPS/IFN-g–treated BMDMs. After
glucose and oligo injections, Slc2a1M2/2 BMDMs in every acti-
vation condition (i.e., unstimulated, LPS/IFN-g, and IL4) dis-
played significantly reduced ECAR. Statistical analysis for each
treatment and genotype at each time point for metabolic traces are
included as Supplemental Table I. In sum, BMDM lacking
GLUT1 displayed significant reductions in glycolysis, glycolytic
capacity, and glycolytic reserve in the LPS/IFN-g–stimulated state
(Fig. 2B, p , 0.01, ,0.0001, and,0.0001, respectively, for Slc2a1fl/fl
versus Slc2a1M2/2). There were no significant changes due to geno-
type in nonglycolytic acidification (50).
Next, mitochondrial stress tests were used to determine po-
tential changes in oxidative metabolism driven by ablation of
GLUT1 (Fig. 2C). Slc2a1fl/fl BMDMs behaved as expected:
LPS/IFN-g–stimulated floxed control BMDMs exhibited a low
OCR relative to unstimulated or IL4-stimulated cells and less
responsiveness to injections to manipulate oxidative metabolism.
In contrast, IL4-stimulated floxed control BMDMs exhibited the
highest maximal respiration upon FCCP-induced uncoupling
compared with unstimulated and LPS/IFN-g–stimulated floxed
control BMDMs (Fig. 2C, 2D). Lack of GLUT1 did not signif-
icantly alter OCR in LPS/IFN-stimulated Slc2a1M2/2 BMDMs
versus floxed controls. The absence of GLUT1 in Slc2a1M2/2
BMDMs significantly reduced maximal respiratory capacity
in both unstimulated and IL4-stimulated cells compared with
control Slc2a1fl/fl BMDMs (Fig. 2C, p, 0.01 and,0.0001 at time
points indicated for Slc2a1fl/fl versus Slc2a1M2/2). Overall basal
and maximal respiration, proton leak, ATP production, and cou-
pling efficiency percentage were not significantly altered by
Slc2a1 genotype (data not shown). However, significant reduc-
tions in spare respiratory capacity percentage were detected in
BMDMs lacking GLUT1 compared with controls in the unstimu-
lated and IL4-stimulated, but not LPS/IFN-g–stimulated (highly
glycolytic) states (Fig. 2D, p , 0.01 or p , 0.001, Slc2a1fl/fl versus
Slc2a1M2/2). Finally, lack of GLUT1 also led to a significant re-
duction in nonmitochondrial respiration (51) in unstimulated and
LPS/IFN-g–stimulated BMDMs (Fig. 2D, p , 0.05 and p , 0.01,
respectively, Slc2a1fl/fl versus Slc2a1M2/2).
FIGURE 1. Slc2a1 deficiency led to metabolic reprogramming of MFs. (A) Generation of murine model and breeding schema. BMDMs from Slc2a1fl/fl and
Slc2a1M2/2 mice were generated. BMDMs were either left unstimulated (unstim) or treated with 5 ng/ml LPS and 10 ng/ml IFN-g or 10 ng/ml IL-4 for 24 h.
(B) qPCR measure of Slc2a1 mRNA. (C) GLUT1 protein was measured by Western immunoblot with b-actin as loading control. GLUT1 is glycosylated,
leading to large smear. (D and E) 3H–2-DG uptake was measured over 10 min in BMDMs (D) and thioglycollate-elicited peritoneal MFs (E). (F) 14C-glucose
oxidation was measured over 120 min. (G) BODIPY-palmitate uptake was measured by flow cytometry. (H) 14C-oleate oxidation was measured over 120 min.
Representative data out of n = 4–5 experiments is shown as mean 6 SEM. ****p , 0.0001, **p , 0.01, *p , 0.05 comparing Slc2a1fl/fl versus Slc2a1M2/2.
Finally, [U-13C]-glutamine metabolic tracer analysis was con-
ducted to determine the contribution of glutamine to intermediary
metabolism as an alternate substrate when glycolysis is blunted in
cells lacking GLUT1 compared with controls. Labeling of cell
lysates by [U-13C]-glutamine was identical between Slc2a1fl/fl
controls and Slc2a1M2/2 BMDMs, demonstrating that the pre-
cursor pool of glutamine was equally labeled between genotypes.
M+5 isotope in glutamate and a ketoglutarate (aKG) and M+4 in
aspartate, succinate, fumarate, malate, citrate/isocitrate, and cis-
aconitate were the most abundant isotopes relative to the total
MID, demonstrating forward tricarboxylic acid cycle metabolism
(Fig. 3A, 3B). Isotopes not shown in Fig. 3 were either non-
detectable in the labeled pool or very minor and were not regu-
lated by genotype but are depicted in Fig. 3B. GLUT1-deficient
BMDMs displayed significantly increased contribution of gluta-
mine to tricarboxylic acid cycle intermediates, starting with
glutamate M+5, which demonstrated an 18% greater enrichment
in GLUT1-deficient versus control BMDMs (p , 0.05). An 8%
increase was also detected in aKG M+5, whereas its by-product,
aspartate M+4, was 32% greater (p, 0.0001) in GLUT1-deficient
BMDMs compared with controls. Similarly, both fumarate M+4
(11% greater, p , 0.05) and malate M+4 (15% greater, p , 0.01)
were elevated in the absence of GLUT1. Twenty-four percent
significantly greater enrichment of citrate/isocitrate M+4 was
measured in GLUT1-deficient BMDM (p = 0.0001 control versus
Slc2a1M2/2). The intermediate between citrate and isocitrate,
cis-aconitate M+4, was also 24% greater (p , 0.0001) in GLUT1-
deficient cells versus controls in line with glutamine-derived for-
ward tricarboxylic acid cycle metabolism. In contrast, succinate
M+4 demonstrated a 23% significantly reduced fractional enrich-
ment in Slc2a1M2/2 BMDMs compared with controls (p , 0.0001),
suggesting dilution of label by anaplerotic substrates. Finally,
citrate/isocitrate M+2 (40% greater, p = 0.0001) and aspartate
M+2 (55% greater, p , 0.05) was measured in Slc2a1M2/2,
demonstrating some contribution of acetyl-CoA–derived carbons
from fatty acid or other substrates, such as amino acids.
Lack of GLUT1 reduced intracellular metabolites within
glycolysis and the PPP
To further elucidate the underlying effects of GLUT1 on MF
substrate metabolism, comprehensive metabolomic profiling was
undertaken. Slc2a1fl/fl and Slc2a1M2/2BMDMs were isolated and
left unstimulated or activated with LPS/IFN-g and then lysed for
metabolite analysis. Principal component analysis revealed that
unstimulated and LPS/IFN-g–stimulated BMDMs were metaboli-
cally distinct with regard to genotype (Fig. 4A). Therefore, we
first compared LPS/IFN-g–stimulated Slc2a1fl/fl control BMDMs to
unstimulated Slc2a1fl/fl control cells. Of 329 biochemicals mea-
sured, LPS/IFN-g activation in Slc2a1fl/fl control BMDMs signifi-
cantly increased 90 metabolites relative to unstimulated controls,
whereas 99 were downregulated (p , 0.05, Supplemental Table II
includes all metabolites quantities, two-way ANOVA results, and
respective p values). Consistent with existing literature (9, 26, 52,
53), several metabolic intermediates were increased by LPS/IFN-g
treatment compared with unstimulated Slc2a1fl/fl cells in central
carbon metabolism pathways, including metabolites of glycolysis,
PPP, and tricarboxylic acid cycle (see cartoons and graphs in Figs.
5, 6, [p , 0.05, p , 0.0001], and Supplemental Table II).
We next compared specific GLUT1-driven genotype effects
on metabolism by investigating Slc2a1-mediated differences
between unstimulated and LPS/IFN-g–stimulated BMDMs me-
tabolites. In unstimulated BMDMs, lack of GLUT1 upregulated
23 and downregulated 110 metabolites compared with floxed con-
trols (p , 0.05, Supplemental Table II). In LPS/IFN-g–stimulated
BMDMs, there were 82 upregulated and 78 downregulated
metabolites in Slc2a1M2/2 compared with Slc2a1fl/fl BMDMs
FIGURE 2. The absence of GLUT1 blunted glycolysis and reduced maximal respiration in BMDMs. Glycolysis (A and B) and mitochondrial
(C and D) stress tests were used to measure the contribution of GLUT1 to BMDM metabolism. Unstimulated (unstim), LPS/IFN-g–, or IL-4–
stimulated BMDMs were analyzed on a Seahorse XF96 Extracellular Flux Analyzer, and data were normalized to DNA content. Measures
were compared by two-way ANOVA for each time across genotypes and treatments [see Supplemental Table I for p values for treatment and
genotype at each time in (A) and (C)]. For (B) and (D), only genotype statistical differences are depicted in graphs for clarity as *p , 0.05,
**p , 0.01, ***p , 0.001, ****,0.0001 Slc2a1fl/fl versus Slc2a1M2 /2 . Means + SEM are shown, with n = 12–24 replicates from n = 3
experiments.
(p, 0.05). Critically, both unstimulated and LPS/IFN-g–stimulated
Slc2a12/2 BMDMs exhibited reduced glucose metabolism, partic-
ularly through the PPP, compared with Slc2a1fl/fl control BMDM,
supporting findings from metabolic phenotyping above. Interest-
ingly, in unstimulated BMDMs, glucose was significantly decreased
in Slc2a1M2/2 compared with Slc2a1fl/fl BMDMs (Figs. 5, 6, [p, 0.05,
p , 0.0001], Supplemental Table II). In both unstimulated and
LPS/IFN-g–stimulated BMDMs, lack of GLUT1 led to significant
reductions in glucose 6-P and fructose 6-P (Fig. 5, p , 0.05,
p , 0.0001). Other glycolytic metabolites, such as fructose 1,6PP
and lactate, were reduced in both states but only reached signi-
ficance in either unstimulated (p , 0.001) or LPS/IFN-g–
stimulated (p , 0.0001) BMDMs, respectively (Fig. 5, p , 0.05,
p , 0.0001). In contrast, in unstimulated MFs, concentrations of
FIGURE 3. GLUT1 deletion in MFs increased the contribution of glutamine to tricarboxylic acid cycle intermediates. (A) BMDMs from age-
matched littermate Slc2a1fl/fl and Slc2a1M2/2 mice were stimulated with LPS/IFN-g and labeled with [U-13C]-glutamine (five blue dots represent
labeled carbons). Fractional enrichments of predominant isotopes M+2 or M4 are shown for each metabolite. Isotopic labeling is noted above for each
of the bar graphs. Gray dots represent carbons coming from other substrates. For clarity, isotopic enrichments minimally contributing to the total pool
are not shown in the tricarboxylic acid cartoon, but all are depicted in (B). n = 3 per genotype in one tracer study. The p values by two-way ANOVA are
indicated above the bars in graphs or next to the legend. ****p , 0.0001, **p , 0.01, *p , 0.05 for Slc2a1fl/fl versus Slc2a1M2/2.
the three-carbon glycolytic intermediates 3-phosphoglycerate, 2-
phosphoglycerate, and phosphoenolpyruvate were significantly
greater in the absence of GLUT1 compared with Slc2a1fl/fl control
BMDMs (Fig. 5, p, 0.05, p, 0.0001). Furthermore, in response to
LPS/IFN-g stimulation, the PPP intermediates 6-phosphogluconate,
ribulose-5-P/xylulose 5P, ribose-5 P, ribose, ribitol, and
sedoheptulose-7-P, as well as the peripheral metabolites xylitol
and UDP-glucuronate, were significantly decreased by lack of
GLUT1 in Slc2a1M2/2 compared with Slc2a1fl/fl BMDMs (Fig. 6,
p , 0.05, p , 0.0001). These data demonstrated that lack of
GLUT1 reduced glycolytic and PPP intermediates.
Analysis of tricarboxylic acid cycle intermediates demonstrated
increases in the absence of GLUT1: citrate, isocitrate, succinate,
and fumarate were increased in GLUT1-deficient cells with
LPS/IFN-g stimulation (Supplemental Table II and p values within;
p , 0.05 to p , 0.0001). Succinate precursor g-aminobutyrate was
also increased in Slc2a1M2/2 compared with Slc2a1fl/fl BMDMs
(p , 0.05 in the unstimulated state). Anaplerotic substrates such as
glutamate and glutamine were reduced in unstimulated Slc2a1M2/2
compared with Slc2a1fl/fl BMDMs (p , 0.0001). In addition,
most amino acids were dramatically reduced in both unstimulated
and stimulated states in the absence of GLUT1 (Supplemental
Table II and p values within; p , 0.05 to p , 0.0001). Taken
together, metabolomics data demonstrated a dramatic shift in
BMDMs lacking GLUT1 away from glycolysis and PPP, with
compensatory increased oxidation of other substrates, such as
fatty acids and amino acids such as glutamine (Supplemental
Table II).
GLUT1 ablation shifted arginine metabolism and polyamine
synthesis in response to activating stimuli
A typical biomarker of classical versus alternative MF activation is
arginine metabolism. Citrulline is produced from arginine as a
coproduct with NO by inducible NO synthase (iNOS) (Nos2) upon
proinflammatory activation (11, 20). Thus, we next investigated
the effect of GLUT1 ablation on arginine metabolism and poly-
amine synthesis. Citrulline was significantly decreased by 50% in
LPS/IFN-g–stimulated BMDMs lacking GLUT1 (Supplemental
Fig. 1, p , 0.0001). In contrast, ornithine and 4-hydroxyproline
were significantly increased in LPS/IFN-g–stimulated Slc2a1M2/2
compared with Slc2a1fl/fl BMDMs (Supplemental Fig. 1, p, 0.0001).
Additionally, the polyamines putrescine, spermidine, and sper-
mine were dramatically increased with LPS/IFN-g stimulation
in the absence of GLUT1 compared with control BMDMs
(Supplemental Fig. 1, Supplemental Table II, p , 0.0001). In the
stimulated state, if arginine metabolism is considered as a ratio of
its metabolites, citrulline to ornithine, an estimate of classical
activation (high citrulline to low ornithine) versus alternative acti-
vation (low citrulline to high ornithine) can be obtained. The ratio of
citrulline to ornithine was a mean of 3.52 in floxed controls and
only 1.02 in BMDMs lacking GLUT1, driven by low citrulline and
high ornithine in Slc2a1M2/2 BMDMs compared with floxed con-
trols (Supplemental Table II). Collectively, the described changes in
arginine metabolites further support a role for GLUT1-mediated
glucose metabolism in metabolic reprogramming of MFs
following exposure to proinflammatory activating stimuli.
Lack of GLUT1 reduced expression of genes associated with
inflammatory signaling and markers of oxidative stress
Substrate metabolism regulates MF phenotype (6, 11, 12, 19, 54, 55),
and in the absence of GLUT1, MFs displayed a substrate switch
from glucose to fatty acid and glutamine metabolism. Thus, we next
used unbiased expression analysis to identify genes with altered ex-
pression. BMDMs were either left unstimulated or treated with
5 ng/ml LPS and 10 ng/ml IFN-g or 10 ng/ml IL-4 for 24 h, as above,
and isolated mRNA was analyzed by microarray analysis. The ma-
jority of genes were regulated by classical activation of BMDM
(Supplemental Table III). Of note, unstimulated MFs did not exhibit
many GLUT1-dependent changes aside from four genes that were
downregulated in Slc2a1M2/2 compared with Slc2a1fl/f BMDMs,
FIGURE 4. Slc2a1 deficiency altered metabolic 
profile and expression of inflammatory and metaboli-
cally relevant genes in MFs. BMDMs from Slc2a1fl/fl 
and Slc2a1M2/2 age-matched littermates were gener-
ated. (A) Principle component analysis was conducted 
after metabolomics on Slc2a1fl/fl and Slc2a1M2/2 
BMDMs treated as unstimulated (Unstim) or LPS/IFN-g 
stimulated. n = 4 per genotype. All metabolites and 
p values are in Supplemental Table II. (B) Heatmap  
representing gene expression in BMDMs treated with 
5 ng/ml LPS and 10 ng/ml IFN-g for 24 h. n = 4 per  
genotype. Yellow is upregulated, and blue is down-
regulated. Pathways, genes, and p values are in 
Supplemental Table III for unstimulated, LPS/IFN-g–, 
and IL-4–stimulated BMDMs.
namely lysozyme 2 (Lyz2; with two probe sets NM_017372 and
ENSMUST00000092163), activating transcription factor 7 (Atf7),
and lysozyme 1 (Lyz1). Likewise, only a handful of genes were
regulated by GLUT1 in IL4-activated MFs, including Lyz2
(ENSMUST00000092163), Lyz2 (NM_017372), Lyz1, Atf7, as well
as arginase 1 (Arg1), which were downregulated in Slc2a1M2/2
compared with Slc2a1fl/fl BMDMs.
In LPS/IFN-g–stimulated MFs, a heat map representing 1376
and 1080 genes up- and downregulated, respectively, showed that
two major groups of genes were differentially regulated by
GLUT1 (Fig. 4B). Importantly, no glucose transporters of the SLC
family were differentially regulated by GLUT1 (Supplemental
Table III). Ingenuity Pathway Analysis revealed that the pathways
most strongly upregulated in LPS/IFN-g–stimulated BMDMs in the
absence of GLUT1 included EIF2 signaling, regulation of eIF4 and
p70S6K signaling, mTOR signaling, unfolded protein response,
protein ubiquitination pathway, phagosome maturation, Ag pre-
sentation pathway, oxidative phosphorylation, and mitochondrial
dysfunction (all pathways are reported in Supplemental Table III,
p , 0.05). Notably, anti-inflammatory defenses were increased in
FIGURE 5. Metabolomic analysis revealed GLUT1-dependent glycolysis. BMDMs from Slc2a1fl/fl and Slc2a1M2/2 age-matched littermates were generated.
BMDMs were left unstimulated (Unstim) or stimulated with 5 ng/ml LPS and 10 ng/ml IFN-g for 24 h. Metabolomic analysis was conducted, and each
metabolite is labeled. n = 4 per genotype. Some metabolites are repeated in Figs. 5 and 6 for clarity. All metabolites and p values are in Supplemental Table II.
Some p values for diet effects were omitted for clarity in figures. ****p , 0.0001, ***p , 0.001, **p , 0.01, Slc2a1fl/fl versus Slc2a1M2/2.
the absence of GLUT1, including inhibitor of NF-kB (Nfkbib),
which blunts LPS-activated TLR signaling (TLR4) (56). Kratz et al.
(4) reported that p62/SQSTM1 was upregulated in metabolically
activated MFs to promote lipid metabolism and limit inflamma-
tion. We also observed upregulation of Sqstm1 in Slc2a1M2/2
compared with Slc2a1fl/f BMDMs, supporting metabolic and
cytokine findings.
Ingenuity Pathway Analysis also revealed downregulation of
pathways related to ROS and intracellular signaling in LPS/IFN-
g–stimulated Slc2a1M2/2 compared with Slc2a1fl/f BMDMs,
including phospholipase C signaling, production of NO and ROS
in MFs, protein kinase A signaling, and integrin signaling (all
pathways are reported in Supplemental Table III, p , 0.05). Down-
regulated genes included genes related to glycolysis and the PPP, such
as hexokinase (Hk1) and hexose-6-phosphate dehydrogenase (glucose
1-dehydrogenase, H6pd). A particularly striking decrease was ob-
served in Stat1, a transcriptional activator and important mediator in
the proinflammatory IFN-g receptor signaling cascade. Finally, in-
tegration of gene expression and metabolite identifiers (including fold
values) were used to generate pathways that were most regulated by
GLUT1 (Table I, p , 0.05). Regulation of both genes and metabo-
lites supported pathway analysis, including GLUT1-mediated regu-
lation glutathione (GSH) (oxidative stress pathway), glycolysis,
arginine, and proline metabolism. Taken together, expression anal-
ysis showed that deletion of Slc2a1 resulted in a less-inflammatory,
potentially immunosuppressive phenotype, with upregulation of
lipid-metabolizing and anti-inflammatory genes such as Nfkbib or
p62/SQSTM1 as well as downregulation of proinflammatory
glycolytic and STAT1/IFN-g–driven pathways.
We next investigated the role of GLUT1 in immune activation.
First, flow cytometric quantification of ROS in live BMDMs
demonstrated significantly reduced ROS in Slc2a1M2/2 compared
with Slc2a1fl/fl BMDMs under both unstimulated and LPS/IFN-g–
stimulated conditions (Supplemental Fig. 2A, 2B, p , 0.05).
Second, we compared GSH and oxidized GSSG concentrations
from metabolomic analysis, as a higher GSH/GSSG ratio indicates
less oxidative stress and a greater capacity to manage oxidative in-
sult. In GLUT1-deficient BMDMs, a significantly increased GSH/
GSSG ratio was observed in LPS/IFN-g stimulation compared with
Slc2a1fl/fl controls, indicative of reduced oxidative stress
(Supplemental Fig. 2C, p , 0.01). Additionally, metabolomic
analysis of methionine sulfoxide, a stable biomarker of oxidative
stress (57), indicated significantly decreased concentrations in
unstimulated Slc2a1M2/2 BMDMs (Supplemental Fig. 2D, p, 0.05
comparing Slc2a1M2/2 to Slc2a1fl/fl). Third, assessment of in-
flammatory cytokines and enzymes by qPCR revealed reduced
FIGURE 6. GLUT1-directed PPP in MFs. BMDMs from Slc2a1fl/fl and Slc2a1M2/2 age-matched littermates were generated. BMDMs were left
unstimulated (Unstim) or stimulated with 5 ng/ml LPS and 10 ng/ml IFN-g for 24 h. Metabolomic analysis was conducted, and each metabolite is labeled.
n = 4 per genotype. Some metabolites are repeated in Figs. 4 and 6 for clarity. All metabolites and p values are in Supplemental Table II. Some p values for
diet effects were omitted for clarity in figures. ****p , 0.0001, ***p , 0.001, **p , 0.01, *p , 0.05 Slc2a1fl/fl versus Slc2a1M2/2.
LPS/IFN-g–stimulated PAI1 (Serpine1, p , 0.05) expression in
Slc2a1M2/2 BMDMs (Fig. 7A). Notably, PAI-1 is known to be
regulated by GLUT1 (11). Expression of iNOS (Nos2), a com-
mon biomarker of classical M1-like activation, was reduced by
over 50% in LPS/IFN-g–stimulated Slc2a1M2/2 BMDMs com-
pared with Slc2a1fl/fl BMDMs (Fig. 7B, p , 0.0001). Moreover,
in cells lacking GLUT1, proinflammatory chemokine MCP-1
(Ccl2) was also significantly reduced at both the mRNA (data
not shown) and protein concentration (Fig. 7D, p , 0.05). In
contrast, Arg1, a marker of M2-like alternative activation upon
IL4 stimulation, was also reduced in the absence of GLUT1,
suggesting that both M1- and M2-like biomarkers were reduced
(Fig. 7C, p , 0.0001). Interestingly, IL-1b displayed an increase
in the absence of GLUT1 in LPS/IFN-g–stimulated cells (Fig.
7D, p , 0.0001). There were no significant changes in other
cytokines, including IL6, IL10, or TNF-a (Fig. 7D). Taken to-
gether, these data suggest an overall reduction in activation in
both M1- and M2-like enzymes with reduced MCP1 chemokine
but no major reductions in typical inflammatory cytokines in the
absence of GLUT1.
Obese Slc2a1M2/2 mice display elevated markers of visceral
adipose MF infiltration without associated metabolic sequelae
Obesity is a chronic inflammatory disease in which elevated MF
content in visceral adipose tissue is an established driver of met-
abolic dysfunction. Hence, we next investigated if a lack of my-
eloid Slc2a1 would reduce HFD-induced obesity and/or impair the
development of obesity-associated sequelae. Male Slc2a1M2/2
and Slc2a1fl/fl mice were randomly weaned onto a LFD (10%
calories from fat) or HFD (45% calories from fat). Body weights
Table I. Integrating metabolites and gene expression reveals which pathways are most significantly (p , 0.05) regulated by GLUT1
Pathway Total Expected Hits p Value
Aminoacyl-tRNA biosynthesis 91 12.0 30 0.00000059
GSH metabolism 79 10.4 27 0.00000099
Glycolysis/gluconeogenesis 89 11.7 26 0.0000400
Galactose metabolism 55 7.2 18 0.00013
Amino sugar and nucleotide sugar metabolism 85 11.2 24 0.00014
Arginine and proline metabolism 102 13.4 27 0.00019
Alanine, aspartate, and glutamate metabolism 58 7.6 18 0.00028
Purine metabolism 237 31.2 48 0.00093
PPP 49 6.5 14 0.0032
Butirosin and neomycin biosynthesis 7 0.9 4 0.0075
Citrate cycle (tricarboxylic acid cycle) 51 6.7 13 0.012
Pyruvate metabolism 65 8.6 15 0.019
Glycosaminoglycan degradation 22 2.9 7 0.019
Valine, leucine, and isoleucine biosynthesis 13 1.7 5 0.020
Pyrimidine metabolism 139 18.3 27 0.021
Sphingolipid metabolism 68 9.0 15 0.028
Biosynthesis of unsaturated fatty acids 29 3.8 8 0.029
Nicotinate and nicotinamide metabolism 41 5.4 10 0.036
Fructose and mannose metabolism 59 7.8 13 0.039
Starch and sucrose metabolism 66 8.7 14 0.045
Kyoto Encyclopedia of Genes and Genomes metabolite and GenBank gene numbers and fold changes (Slc2a12/2/Slc2a1fl/fl) were entered into Metaboanalyst for
pathway analysis.
FIGURE 7. Lack of GLUT1 led to reduced activation. BMDMs from Slc2a1fl/fl and Slc2a1M2/2 age-matched littermates were generated. BMDMs
were left unstimulated (Unstim) or stimulated with 5 ng/ml LPS and 10 ng/ml IFN-g or 10 ng/ml IL-4 for 24 h. (A–C) qPCR analysis was conducted
on M1-like markers, including Serpine1 (PAI-1), Nos2 (iNOS), and M2-like marker Arg1. n = 3 replicates in three experiments. (D) Luminex protein
analysis was used to measure concentrations from conditioned media of chemokine Ccl2 (MCP-1), and cytokines IL1b, IL6, Il10, and TNF-a.
Mean 6 SEM is shown. n = 4–6. ****p , 0.0001, *p , 0.05 Slc2a1fl/fl versus Slc2a1M2/2.
did not reveal significant differences driven by GLUT1 in lean or
obese mice (data not shown).
Interestingly, despite a lack of significant genotype-driven dif-
ferences in weight gain, body composition, or fat pad mass in obese
Slc2a1M2 /2 mice compared with floxed controls, eWAT in
Slc2a1M2/2 mice displayed 5-fold elevated MCP-1 (Ccl2) ex-
pression compared with Slc2a1fl/fl mice (Fig. 8E, p , 0.001).
Adipose MF infiltration was next analyzed via expression of MF
marker Emr1 (F4/80) and immunohistochemical analysis of F4/80+
MF staining. Emr1 mRNA expression was more than doubled in
HFD-fed Slc2a1M2/2 mice compared with Slc2a1fl/fl mice (Fig. 8F,
p , 0.001). Immunohistologic detection of F4/80 indicated that
although there was no genotype effect within diet, CLS were in-
creased by a HFD in obese compared with lean Slc2a1M2/2 mice,
whereas no significant diet effect was observed for Slc2a1fl/fl mice
(Fig. 8G, 8H, p , 0.0001 LFD versus HFD in Slc2a1M2/2 mice).
Therefore, to investigate the long-term effects of GLUT1 ablation
on adipose MF infiltration, a subset of mice was maintained on a
LFD or HFD for ∼10 mo (an average of 46.13 wk; n = 4 per diet
and genotype). At this time point, older, obese, HFD-fed Slc2a1fl/fl
and Slc2a1M2/2 mice both exhibited significantly increased body
weight and fasting glucose relative to lean animals, with no
FIGURE 8. Obese Slc2a1M2/2 mice displayed greater chemokine expression and greater markers of MF infiltration in eWAT. Age-matched Slc2a1fl/fl
and Slc2a1M2/2 littermates were weaned onto 10% (LFD) and 45% (HFD) kcal from fat diets at 3 wk of age and maintained on diet. (A) Body weight was
measured as indicated. ^p , 0.05 in Slc2a1fl/fl LFD mice versus HFD mice from 3 wk until harvest and in Slc2a1M2/2 LFD mice versus HFD mice from
7 wk until harvest. *p , 0.05 Slc2a1fl/fl versus Slc2a1M2/2 in LFD only. (B) Six hours fasted blood glucose at 21 wk of age. p , 0.01 LFD versus HFD.
***p , 0.001 and ****p , 0.0001 HFD versus LFD. (C) MRI analysis of adiposity was quantified at 1, 4, 7, and 20 wk on diet. (D) eWAT was weighed
at sacrifice. ***p , 0.001, Slc2a1fl/fl versus Slc2a1M2/2. (E and F) qPCR analysis of eWAT expression of chemokine Ccl2 (MCP1) and MF marker Emr1
(F4/80). ***p , 0.001, Slc2a1fl/fl versus Slc2a1M2/2. (G) F4/80+ immunohistochemical analysis of eWAT. CLS are indicated by arrows. Representative
images shown (original magnification 320). Scale bar, 100 mm. (H) CLS were quantified in six random F4/80+ stained fields. ^^^p , 0.0001 for LFD
versus HFD in Slc2a1M2/2 mice compared with Slc2a1fl/fl mice. n = 14–19 mice.
were significantly greater in HFD-fed mice compared with LFD-
fed mice, as expected, starting at 3 wk following diet start in 
Slc2a1fl/fl mice and 7 wk in Slc2a1M2/2 mice (Fig. 8A, *p , 0.01, 
LFD versus HFD). Interestingly, from 5 wk on diet until sacrifice, 
lean Slc2a1M2 /2 mice were significantly heavier than lean 
Slc2a1fl/fl controls (Fig. 8A, p , 0.05). Notably, Slc2a1fl/fl mice 
developed fasting hyperglycemia on a HFD (Fig. 8B, p , 0.01), 
whereas Slc2a1M2/2 mice did not. However, although glucose 
tolerance and insulin tolerance were impaired following prolonged 
HFD exposure, no genotype-driven effects were observed (data 
not shown). Body composition as measured by MRI demonstrated 
HFD-induced fat accretion with elevated, but nonsignificant, in-
creases in fat mass in Slc2a1M2/2 compared with Slc2a1fl/fl mice 
(Fig. 8C). HFD exposure increased eWAT pad mass equally in 
Slc2a1fl/fl and Slc2a1M2/2 mice (Fig. 8D, p , 0.001 in Slc2a1fl/fl 
mice and p , 0.0001 in Slc2a1M2/2 mice, comparing LFD versus 
HFD). There were no significant effects of GLUT1 deficiency on 
lean mass for either diet (data not shown). Similarly, measurement 
of liver and brown adipose tissue weights indicated significantly 
increased mass of both in HFD-fed mice (p , 0.0001), yet no sig-
nificant GLUT1-mediated effects were observed (data not shown). 
Additionally, energy expenditure experiments using metabolic cages
significant differences by genotype (data not shown). Interestingly,
despite an ∼2-fold difference in total adiposity, eWAT mass did not
significantly differ between lean and obese animals following pro-
longed obesity (Supplemental Fig. 3A, 3B). However, adipose pads
of older obese mice exhibited discoloration that was not observed in
lean animals (image in Supplemental Fig. 3B) or younger obese
mice from previous analyses. Individual eWAT pads were collected
and dissociated for flow cytometric analysis of total adipose
immune invasion, total myeloid cell content, and MF content.
Total stromal-vascular cells in obese mice were elevated ∼3-fold
relative to lean mice, with no genotype-driven difference detected
(Fig. 9A). Similarly, total CD45+ immune cell content as a percentage
of stromal-vascular cells was not significantly altered by diet or ge-
notype (Fig. 9B), nor was CD11b+ myeloid cell content as a per-
centage of total immune cells (Fig. 9C). However, as a percentage of
myeloid cell content, CD64+ MFs were increased nearly 2-fold in
obese mice (Fig. 9D), which translated to a dramatic increase in the
number of MFs per gram of adipose (Fig. 9E). Neither adipose MF
content nor percent contribution to the myeloid fraction was altered by
the absence of GLUT1. Together, these results indicate that GLUT1
ablation did not alter adipose infiltration by MFs or other myeloid
subsets potentially affected by LysMCre-driven Slc2a1 deletion.
However, lack of GLUT1 increased expression of CD64 (FcgRI) in
adipose MFs of both lean and obese Slc2a1M2/2 mice relative to
Slc2a1fl/fl controls (Fig. 9F, ****p, 0.0001, lean versus obese; p = 0.
022 Slc2a1fl/fl versus Slc2a1M2/2). CD64 is a definitive MF marker,
and its expression has been reported to be modulated by both IFN-g
and IL-10, suggesting roles in both inflammatory response and
resolution following insult. Percentage of adipose MFs expressing
CD206 was not influenced by diet or genotype (Supplemental Fig.
3C, 3D), but MF CD206 expression was elevated in response to
GLUT1 ablation in lean animals (Fig. 9G, p = 0.040, Slc2a1fl/fl
versus Slc2a1M2/2), indicating increased CD206 surface expression
by individual MFs. Interestingly, this increase in CD206 expression
was not observed in obese Slc2a1M2/2 mice. Overall, these data
show that myeloid GLUT1 deletion does not dramatically influence
systemic metabolism or immune infiltration of visceral adipose in
response to prolonged obesity, even in aged mice. However, findings
FIGURE 9. Myeloid-specific GLUT1 ablation affected phenotype, but not infiltration, of adipose tissue MFs in older mice. (A) Total cell count within
the SVF was normalized to eWAT mass. ****p , 0.0001, lean versus obese. (B) CD45+ leukocytes as a percentage of total SVF cells. (C) CD11b+ myeloid
cells as a percentage of total (CD45+) adipose leukocytes. (D) CD64+ MFs as a percentage of total (CD11b+) myeloid cells. ****p , 0.0001, lean versus
obese. (E) Adipose tissue MF content was calculated as the number of MFs per gram of tissue. ****p , 0.0001, lean versus obese. (F) CD64 expression
quantified as MFI. ****p , 0.0001, lean versus obese; *p = 0.022 Slc2a1fl/fl versus Slc2a1M2/2. (G) CD206 expression quantified as MFI. *p = 0.040,
Slc2a1fl/fl versus Slc2a1M2/2. Representative pseudo-color dot plots shown for lean mice. n = 4 per diet and genotype.
did not alter the susceptibility of Ldlr2/2 mice to gain weight
(Supplemental Fig. 4B) or change fasting plasma glucose over the
course of the study (Supplemental Fig. 4C) compared with Slc2a1fl/fl
Ldlr2/2 mice. Similarly, Slc2a1M2/2Ldlr2/2 mice did not exhibit
altered systolic or diastolic blood pressure at 16 wk of age relative
to Slc2a1fl/flLdlr2/2 control mice (data not shown). Finally, deletion
of myeloid Slc2a1 did not alter body composition of recipient mice
(i.e., percentage of lean or fat mass) as measured by MRI at 5, 10,
16, and 22 wk of age, corresponding to before BMT, before diet,
6 wk on diet, and at sacrifice after 12 wk on diet (data not shown).
Interestingly, total cholesterol (Supplemental Fig. 4D, p , 0.0196)
and LDL cholesterol (Supplemental Fig. 4E, p , 0.017) concen-
trations in plasma after 12 wk on Western diet were 20 and 23%
greater, respectively, in Slc2a1M2/2 Ldlr2/2 compared with control
Slc2a1fl/flLdlr2/2 mice. Total plasma high-density lipoprotein
(HDL) and triglyceride concentrations were not altered by Slc2a1
deletion (data not shown, respectively).
After 12 wk of diet (at 22 wk of age), mice were terminated, and
aortic root lesions were analyzed. Lack of GLUT1 did not lead to
FIGURE 10. Slc2a1M2/2 Ldlr2/2mice displayed unstable lesions, and lack of GLUT1 led to phagocytic defects. Marrow from Slc2a1fl/fl and Slc2a1M2/2mice
was transplanted into Ldlr2/2, and mice were fed a Western diet for 12 wk. (A) Serial interrupted 10-mm sections were stained with ORO and counterstained with
hematoxylin. Representative photomicrographs (original magnification 320) of ORO staining are shown. n = 8. (B) Quantification of lesion area. (C) Serial
interrupted 5-mm sections were immunostained with anti-MOMA2 and counterstained with methyl green. Representative photomicrographs (original magnifi-
cation 320) are shown. n = 8. (D) Quantification of MOMA2+ content. n = 8. (E) Serial interrupted 5-mm sections were stained with Masson’s trichrome (MT).
Representative photomicrographs (original magnification 320) are shown. Necrotic core indicated with asterisk (*). n = 8 (F) Quantification of collagen content.
**p , 0.01. (G) Quantitative analysis of the percentage of mice with necrotic cores. (H and I) Ten-micrometer IgG-coated carboxylated microsphere adherence
and uptake assay was conducted over 20 min. Fixed MFs were stained with phalloidin-AF488 for actin (green), Rhodamine Red-X for extracellular adherent
beads (magenta), and Cy5 (red) for total (adherent and engulfed) beads following permeabilization. Zeiss LSM Image Browser was used to circle engulfed 10-mm
beads. Blue DAPI was not shown for clarity. (I) Quantification of adherent and engulfed beads. *p, 0.05, Slc2a1fl/fl/Ldlr2/2 versus Slc2a1M2/2 Ldlr2/2.Mean6
SEM. n = 3–4 experiments. ^p , 0.05, Slc2a1Fl/Fl adherent versus engulfed beads. Representative images (original magnification 340) are shown.
suggest phenotypic differences in MFs lacking GLUT1, such as 
elevated expression of canonical MF markers, suggest the potential 
for as-yet undetected alterations in adipose tissue homeostasis.
Myeloid GLUT1 deficiency decreased stability of 
atherosclerotic plaques
As expression of MF-associated inflammatory mediators and 
metabolism is also crucial in atheroma formation, we hypothesized 
that MF contribution to atherogenesis may be altered by GLUT1 
deficiency. To determine the effects of a lack of Slc2a1 on athero-
genesis, bone marrow from Slc2a1fl/fl and Slc2a1M2/2 donors was 
transplanted into 10-wk-old lethally irradiated mice lacking LDL 
receptor (Ldlr2/2). Control unreconstituted Ldlr2/2 recipient mice 
(transplanted with vehicle HBSS buffer only) died by 10–11 d after 
irradiation, confirming successful endogenous bone marrow deple-
tion (data not shown). Four weeks after reconstitution, Slc2a1fl/fl 
Ldlr2/2 and Slc2a1M2/2Ldlr2/2 mice were exposed to Western diet 
for the remainder of the study to induce atherogenesis (58) (see 
study design in Supplemental Fig. 4A). Deletion of myeloid Slc2a1
significant differences in total lesion size in the aortic root com-
pared with control Slc2a1fl/fl Ldlr2/2 mice (Fig. 10A, 10B). There
was also no GLUT1-driven difference in the number of sub-
endothelial cells per total lesion area between Slc2a1M2/2Ldlr2/2
compared with Slc2a1fl/flLdlr2/2 mice (data not shown). Thus, we
next quantified MOMA2-positive MF content. No significant
differences were observed in MF content in lesions of
Slc2a1M2 /2Ldlr2 /2 compared with Slc2a1fl/flLdlr2 /2 mice
(Fig. 10C, 10D). Thus far, data suggested that myeloid GLUT1
does not alter lesion size or MF content. However, the noncellular
composition of the intimal lesions such as collagen content can
alter plaque stability (59), which was, in fact, dramatically al-
tered by Slc2a1 deficiency. Atheromas in Slc2a1M2/2Ldlr2/2
mice contained significantly less collagen compared with
Slc2a1fl/fl Ldlr2/2 mice (Fig. 10E, 10F, p , 0.0065). Moreover,
87% of Slc2a1M2/2Ldlr2/2 mice displayed necrotic core for-
mation (seven out of eight mice), compared with only 37.5% of
control Slc2a1fl/fl Ldlr2/2 mice (three out of eight mice,
Fig. 10G). Thus, although few systemic defects were present,
significant local changes to the vessel microenvironment led to
unstable necrotic lesions in the absence of myeloid GLUT1.
Finally, glucose plays an important role in actin polymerization
(60) as well as MF clearance of apoptotic cells, a type of
phagocytosis called efferocytosis (61). Altering phagocytosis of
LDL/ox-LDL and/or efferocytosis could potentially influence the
accumulation of necrotic material. Thus, we examined whether
Slc2a1M2/2 MFs displayed defects in phagocytic capacity com-
pared with Slc2a1fl/fl MFs. Carboxylated microsphere phagocyto-
sis assays were used to model particle uptake akin to efferocytosis,
thereby testing the role of GLUT1 in binding and engulfment
(62–64) in Slc2a1fl/fl and Slc2a1M2/2 MFs (Fig. 10H, 10I). How-
ever, whereas Slc2a1fl/fl MFs engulfed beads efficiently (p , 0.05
adherent versus engulfed), MFs lacking GLUT1 displayed a sig-
nificantly reduced (38%) capacity to engulf microspheres (Fig. 10H,
10I, p , 0.007 comparing Slc2a1M2/2 to Slc2a1fl/fl). In summary,
these results suggest that efferocytosis may be impaired in the ab-
sence of GLUT1, potentially contributing to the accumulation of
necrotic debris in lesions of Slc2a1M2/2 mice.
Discussion
A spectrum of MF activation phenotypes exist in tissue micro-
environments that can be characterized by differential surface
marker expression, cytokine repertoire, and metabolic profile
(1, 8). Immune cell function is reliant upon intracellular metabolism to
generate immune responses and maintain tissue homeostasis (8, 9, 65–
67). We and others have shown that metabolic reprogramming and
resulting substrate preference in response to activating stimuli play
pivotal roles in immune cell biology, acting as a determinant of in-
flammatory potential in MFs and dictating functionality of NK, T, and
B cells (9, 11–13, 19, 54, 66, 68–72). Based on the importance of
metabolism in determining immunophenotype and response, nutrient
transporters may be excellent targets to regulate MF activation and
subtypes, allowing these immune cells to be successfully targeted
through approaches such as nanoparticle delivery (73–76).
In the current studies, we hypothesized that the glucose trans-
porter GLUT1 acts as a gatekeeper to a robust glycolysis/PPP-
associated proinflammatory response in MFs. To this end, we
successfully created a unique murine model in which glucose
metabolism was blunted in a myeloid-specific manner. Indeed,
in the absence of GLUT1, BMDMs and thioglycollate-elicited
peritoneal Slc2a1M2/2 MFs failed to uptake glucose in the
basal or alternatively activated states, in which glucose use is
minimal. Upon LPS/IFN-g stimulation, minimal glucose uptake
was evident in BMDMs lacking GLUT1, suggesting minor uptake
was possible, likely through contaminating cells in BMDM prepa-
ration. Indeed, no increase in glucose uptake was present in
thioglycollate-elicited LPS-stimulated MFs. We have previously
published that GLUT3 is expressed at the limit of detection in
BMDMs and is, in fact, downregulated with LPS/IFN-g stimulation
(11). Gene expression analysis presented in this article supports
that no glucose transporters of the SLC family were differentially
regulated in the absence of GLUT1. Taken together, the overall lack
of glucose uptake in Slc2a1M2/2 MFs supports that 1) GLUT1 is
the primary glucose transporter in MFs, and 2) there was no
compensatory upregulation of other glucose transporters.
The metabolic impact of GLUT1 deletion on MF substrate use
demonstrated that in the absence of GLUT1, Slc2a1M2/2 BMDMs
resorted to elevated fatty acid uptake and oxidation as well as
greater glutamine oxidation. Cellular bioenergetics analysis
demonstrated that glycolysis, as measured by ECAR, was dra-
matically blunted in the absence of GLUT1, even in response to
stimuli that typically increase glycolysis (LPS/IFN-g). OCR mea-
surements suggested no defects in basal respiration; however, res-
piration was blunted by the lack of GLUT1 in the uncoupled state
after FCCP injection, indicating that maximal flux through the
electron transport chain was not sustainable. Interestingly,
[14C]-oleate fatty acid oxidation was elevated with specific stimuli
in cells lacking GLUT1. [U-13C]-glutamine metabolic tracer anal-
ysis determined that glutamine contributed to intermediary meta-
bolism as an anaplerotic substrate in GLUT1-deficient BMDMs.
Compared with control BMDMs, in Slc2a1M2/2 BMDMs, most
metabolites of the tricarboxylic acid cycle demonstrated signifi-
cantly enriched M+4 or M+5 isotopes. Nominal but significantly
enriched M+2 citrate/isocitrate and aspartate suggest glutamine
contributed two carbons to the pool of citrate/isocitrate, yielding the
M+2 isotope (through pyruvate and acetyl-CoA) with other carbons
likely derived from substrates such as fatty acids or amino acids
through acetyl-CoA in the absence of GLUT1-mediated glycolysis.
Overall, tracer studies are consistent with glutamine use as an
anaplerotic substrate when GLUT1 is absent. Of note, succinate
enrichment was significantly reduced in Slc2a1M2/2 BMDMs
compared with controls, which could be explained by unlabeled
anaplerotic substrates such as branched-chain amino acids entering
at succinate through succinyl-CoA (77). Thus, further study of
glutamine and branched-chain amino acid transport and metabolism
with respect to GLUT1 deletion or inhibition should be evaluated.
Together, these data suggest a flexibility in MF metabolism yet an
inability to fully compensate for a lack of GLUT1. It is possible that
there is a defect in mitochondrial content in the absence of GLUT1.
In sum, in cells driven toward an increased dependence on
glycolysis in response to LPS/IFN-g, the lack of GLUT1 pre-
vented glycolysis and PPP metabolism. In cells that are unstimu-
lated or activated to be primarily oxidative with IL4 stimulation, the
lack of GLUT1 hindered the ability to increase broad oxidative
metabolism when needed, as demonstrated by reduced maximal
respiration. Future studies will determine GLUT1-mediated
changes to mitochondrial content, mitophagy, and additional
analysis of specific metabolite transport and metabolism.
Comprehensive metabolomic analysis revealed that glycolytic
intermediates glucose-6-P and fructose-6-P were decreased in
Slc2a1M2/2 versus Slc2a1fl/fl BMDMs, consistent with decreased
glucose availability and reduced glycolytic flux. Additionally, we
observed a dramatic decrease in nearly every PPP intermediate in
Slc2a1M2/2 BMDMs, consistent with reduced glucose availabil-
ity. Of note, glucose was still detected in GLUT1-deficient
BMDMs stimulated by LPS/IFN-g, suggesting that this glucose
could be accounted for by the small amount of glucose taken up
by contaminating cells in the LPS/IFN-g–stimulated BMDMs
regulated by the absence of GLUT1. In classically activated,
proinflammatory MFs, citrulline is produced from arginine as a
coproduct with NO by iNOS (Nos2) (11, 20). NO is a highly
unstable radical that nitrosylates and thereby inactivates compo-
nents of the electron transport chain, which further drives gly-
colysis because oxidative metabolism is reduced (21). In this way,
arginine acts as a central node in both inflammation and meta-
bolism. Although NO cannot be measured directly in tissue, cit-
rulline concentration acts as a surrogate marker for diversion of
arginine toward inflammatory products. Importantly, the lack of
GLUT1 in Slc2a1M2/2 BMDMs reduced both cellular citrulline
levels and iNOS mRNA expression compared with Slc2a1fl/fl
BMDMs, supporting a role for GLUT1 in the regulation of the
iNOS proinflammatory pathway. In Slc2a1M2/2 GLUT1-deficient
BMDMs, low citrulline levels were also concomitant with high
ornithine, a shift in metabolism resembling the alternative M2-like
phenotype. In alternatively activated MFs, arginine is preferen-
tially metabolized to ornithine, which is shunted into the synthesis
of polyamines, molecules associated with extracellular matrix
remodeling during wound healing or tissue growth. Importantly,
polyamines are critical mediators of IL-4–induced alternative MF
activation and greatly elevated in the absence of GLUT1 (82, 83).
For example, spermine reportedly blunts LPS-induced secretion
of proinflammatory cytokines in both mouse and human MFs
(84, 85), whereas polyamine-depleted MFs show an increased
inflammatory response (86–88). Additional downstream ornithine
metabolites include proline and 4-hydroxyproline, both of which
are also involved in matrix remodeling. The concentration of
4-hydroxyproline was greater in Slc2a1M2/2 BMDM compared
with concentrations in Slc2a1fl/fl BMDM. In sum, GLUT1 ma-
nipulation resulted in striking and reciprocal effects on polyamine
synthesis, as evidenced by a dramatic increase in response to
GLUT1 deletion (this manuscript) along with potent downregu-
lation following GLUT1 overexpression as we previously reported
(11). These findings suggest that GLUT1 deletion may hold po-
tential for increased extracellular matrix remodeling during reso-
lution of the inflammatory response, a hypothesis that could be
tested in models of infectious disease.
In accordance with the observed GLUT1-mediated metabolic
changes, GLUT1 ablation also skewed the BMDMs toward a
less-activated phenotype overall. Slc2a1M2/2 BMDMs failed to
fully classically M1 polarize in vitro, showing reduced expression
of proinflammatory mediators, including reduced iNOS and
MCP1. However, GLUT1 did not alter secretion of IL6, IL10, or
TNF-a. Moreover, glycolysis in classically activated MFs has
been shown to be essential for IL-1b production (9, 12), yet IL-1b
was not reduced in the absence of GLUT1. In fact, it was elevated,
albeit with great variability in concentrations (89, 90). Upregula-
tion of the M2-associated enzyme Arg1 was, in fact, blunted
following IL-4 stimulation in BMDMs lacking GLUT1. Thus,
similar to our metabolomics and bioenergetics findings, the
GLUT1-deficient inflammatory phenotype was neither purely pro-
nor anti-inflammatory but, instead, mixed phenotype, perhaps in-
dicating stunted activation. A potential mechanism explaining this
paradoxical phenotype was a significant reduction in STAT1 ex-
pression in MFs deficient for GLUT1, which mediates IFN-g sig-
naling to polarize MFs toward the proinflammatory phenotype (91),
but these and other pathways remain to be studied in the future.
We next assessed the ability of MFs to generate a functional
immune response in the absence of GLUT1-mediated glucose
availability. Metabolomic and flow cytometric analysis of ROS
production showed reduced ROS and methionine sulfoxide in
Slc2a1M2/2 BMDMs following LPS/IFN-g activation as well as
greater capacity to combat oxidative stress (higher GSH/GSSG
(discussed above) or possibly created by gluconeogenesis or 
released by glycogenolysis, and it may be metabolized at a slower 
rate. Indeed, reduced expression of hexokinase 1 (Hk1; Supplemental
Table III), ∼3-fold lower concentrations of downstream metabolites in 
glycolysis, and reductions in ECAR together support a defect in 
glycolysis because the absence of GLUT1. Furthermore, comple-
mentary findings were reported in our previous work, wherein greater 
glucose uptake and PPP metabolites were observed in response to 
GLUT1 overexpression studies in MFs (11). Reduced glycolysis in 
the absence of GLUT1 led us to question whether Slc2a1M2/2 MFs 
would show increased reliance on other metabolic pathways. In this 
study, significantly increased concentrations of tricarboxylic acid cycle 
intermediates (including citrate, isocitrate, succinate, and fumarate) 
were detected in Slc2a1M2/2 BMDMs stimulated by LPS/IFN-g. 
These elevated tricarboxylic acid cycle intermediates were likely de-
rived from anaplerosis, such as elevated glutamine metabolism (as we 
demonstrated) or other substrates (9, 10, 12). An increased reliance of 
Slc2a1M2/2 BMDMs upon anaplerotic substrates such as glutamine is 
further supported by the observed reductions in intracellular levels of 
most of the proteinogenic amino acids. Amino acid catabolism can 
contribute to pyruvate and other three-carbon intermediates in lower 
glycolysis, such as phosphoenolpyruvate, 2-PG, and 3-PG, which were 
elevated in cells lacking GLUT1. Dipeptides were also increased, 
suggesting protein degradation to fuel anaplerosis. In sum, lack of 
GLUT1 redirected substrate metabolism from glucose and glycolysis 
toward oxidative and anaplerotic metabolism.
LPS/IFN-g–activated M1-like MFs become metabolically 
reprogrammed through two main blocks, or “brakes,” in the tri-
carboxylic acid cycle (9, 10). First, classical activation reduces 
expression of the enzyme isocitrate dehydrogenase (Idh), which 
leads to an accumulation of citrate (78). Citrate plays many im-
portant roles in MFs; it can drive proinflammatory responses such 
as lipid synthesis necessary for Ag presentation as well as regulate 
ROS and/or NO production, reviewed in detail in Van den Bossche 
et al. (9). For instance, citrate-derived itaconate is increased by 
LPS/IFN-g and is responsible for the second break in the tricar-
boxylic acid cycle through inhibition of succinate dehydrogenase 
(SDH1). Less SDH1 activity leads to reduced oxidative meta-
bolism and allows for the increased glycolytic flux needed for 
proinflammatory activation (79–81) through reduced tricarboxylic 
acid cycle as well as SDH- containing complex II in the electron 
transport chain. Yet checkpoints are also in place that provide neg-
ative feedback to prevent too strong of a proinflammatory response. 
Itaconate itself also acts as an immunosuppressive anti-inflammatory 
metabolite that downregulates ROS, iNOS, and certain cytokine 
production (21). In this study, the observed increase in citrate in 
Slc2a1M2/2 BMDMs compared with controls is paradoxical because 
citrate is typically a biomarker of classical M1-like activation, and 
cells lacking GLUT1 appear incapable of complete M1-like acti-
vation. In the absence of GLUT1, reduced ROS was detected even in 
the presence of greater concentrations of citrate relative to floxed 
controls. Reduced ROS in the absence of GLUT1 may be explained 
by the homeostatic mechanism of citrate-derived itaconate inhibiting 
both SDH1 and reverse electron transport–derived ROS production, 
as increased itaconate was also detected in cells lacking GLUT1. 
Taken together, our findings indicate that lack of GLUT1 prevented 
complete activation to a classical phenotype in response to LPS/IFN-g 
stimulation and suggest a greater dependence on fatty acid metabolism, 
supportive of a shift toward an alternative M2-like phenotype. Future 
studies will entail detailed flux analysis to determine to what 
extent glucose versus certain fatty acids versus glutamine are 
metabolized in a GLUT1-regulated manner.
A main component of pro- versus anti-inflammatory MF phe-
notypes is arginine metabolism (82), which was dramatically
ratio). Reduced oxidative stress in MFs lacking GLUT1 is com-
plementary to our previously published work, wherein over-
expression of GLUT1 induced elevated ROS production and
markers of oxidative stress (11). Interestingly, methionine sulf-
oxide was significantly reduced in cells lacking GLUT1 compared
with Slc2a1fl/fl BMDMs; this metabolite is not just a marker of
oxidative stress but can also lead to classical (M1) polarization
in vitro (57). These findings may be explained by the reduction of
flux through the PPP in cells lacking GLUT1, as PPP flux is re-
quired in classical M1-like activation for ROS (through NADPH
oxidase) and NO production, yet it is not required in alternative
activation (92). In sum, pathways downstream of GLUT1 that
produce ROS, as well as metabolic intermediates capable of MF
proinflammatory activation and markers of oxidative stress, were
reduced in Slc2a1M2/2 BMDMs.
Taken together, the overall phenotype of GLUT1-deficient
BMDMs was primarily less proinflammatory, which led us to
question the role of GLUT1 in MF biology in systemic disease.
Obesity is associated with low-grade adipose inflammation and
oxidative stress following MF infiltration into epididymal and
brown adipose depots as well as other adipose depots including
the human breast and normal mouse mammary gland (19, 20, 28,
31, 43, 93–98). Indeed, adipose tissue MFs appear to be a unique
phenotype distinct from MF subtypes described in other tissues
(1). Early characterization of adipose tissue MF populations first
described the obesity-induced appearance of proinflammatory
MFs in conjunction with elevated levels of proinflammatory cy-
tokines and chemokines such as TNF-a, IL6, and CCL2 (99, 100).
However, recent extensive profiling of adipose tissue MFs from
adipose tissue of obese mice and humans has revealed a “mixed”
pro- and anti-inflammatory phenotype (101–106). Considering the
complexity of phenotyping MFs by surface markers and expres-
sion profiling, the contribution of underlying metabolic parameters
has the potential to inform us about MF phenotype and function
in adipose tissue of obese individuals. Therefore, we sought to
determine the contribution of myeloid GLUT1 to the develop-
ment of obesity and its associated inflammatory sequelae. Despite
the pronounced metabolic and inflammatory changes observed in
Slc2a1M2/2 BMDMs, in vivo obesity studies unexpectedly
revealed only subtle findings. Slc2a1M2/2 mice did not display
differences in body weight, body composition, or insulinemia
compared with floxed controls when fed an obesogenic HFD.
However, following 20 wk on a HFD, control mice developed
fasting hyperglycemia compared with lean controls, whereas
Slc2a1M2/2 mice did not, suggesting protection from diet-induced
defects in glycemic control, albeit subtle. In contrast, subsequent
analyses did not reveal significant GLUT1-mediated differences in
glucose or insulin tolerance. Interestingly, long-term exposure
(.40 wk) to HFD-induced obesity resulted in hyperglycemia in
both floxed control and Slc2a1M2/2 mice, suggesting that the loss
of myeloid GLUT1 prolonged development of hyperglycemia but
was not fully protective against obesity-associated systemic
pathological conditions, such as metabolic dysregulation. The lack
of prominent genotype-driven systemic metabolic abnormalities
allowed for a tissue-specific focus on the role of myeloid GLUT1
in the adipose microenvironment. Histologic and flow cytometric
analyses of adipose tissue MFs revealed no significant genotype-
driven differences in adipose MF content in either lean or obese
mice. Thus, MF were able to infiltrate (or proliferate) in adipose
tissue even in the absence of GLUT1. Of note, a greater con-
centration of CCL2 was observed in the adipose tissue of
Slc2a1M2/2mice compared with Slc2a1fl/fl controls. MCP-1 is
known to be produced by adipocytes in obesity, suggesting that
despite adequate MF infiltration, a distress signal continued to be
secreted in the adipose tissue of myeloid GLUT1-deficient mice.
Thus, GLUT1-deficient adipose tissue MFs are present, but they
are not “effective” in promoting typical comorbidities associated
with obesity, such as glucose intolerance. Critically, expression of
the typically M2-like alternative marker CD206 (mannose recep-
tor) was elevated in adipose tissue MFs from lean Slc2a1M2/2
mice, a finding also observed at the mRNA level in in vitro,
unstimulated BMDMs, which is indicative of an adipose tissue
MF of an alternative or M2-like phenotype. Collectively, our data
suggest that the phenotypic shift toward alternative M2-like adi-
pose tissue MFs in the absence of GLUT1 may have transiently
protected mice from typical concomitant metabolic sequelae as-
sociated with obesity. However, this protection was lost with
prolonged obesity in older mice. These data emphasize that de-
spite dramatic defects in glycolysis, PPP, and ROS production, the
metabolic flexibility of MFs can compensate enough through
anaplerotic and other substrate metabolism that lead to only subtle
defects in diet-induced obese mice lacking myeloid GLUT1.
Because obesity and atherosclerosis share common inflamma-
tory etiologies, we next aimed to investigate how myeloid GLUT1
affected atherosclerosis. Atherosclerosis is linked to many risk
factors, including obesity (26, 107). MFs are involved in almost
every stage of atherosclerosis, with MF glycolysis associated with
poorer outcomes (108). In the early stage, MFs become foam
cells through the unabated engulfment of lipids, clearance of
neighboring dead cells (termed “efferocytosis”), and secretion of a
spectrum of proinflammatory cytokines, ROS, and reactive nitro-
gen species. In the advanced stage, MFs promote the death of
smooth muscle cells and release matrix-degrading enzymes and
procoagulant tissue factors (107, 109). Both classically and al-
ternatively activated MFs are present in atherosclerotic lesions
(110). The proinflammatory MF phenotype has been reported to
be associated with plaque progression, whereas the immunosup-
pressive M2-like phenotype is linked to reduced lesion size and
plaque regression (108, 111–116). Furthermore, atheromas are
also known to take up high levels of glucose (117). Therefore,
using a BMT strategy, we generated mice with LysMCre–driven
ablation of Slc2a1 in an atherogenic LDL receptor–deficient
model. There were no differences in lesion size in Slc2a1M2/2
Ldlr2/2 compared with Slc2afl/fl Ldlr2/2 mice. Minor GLUT1-
dependent increases in plasma total and LDL cholesterol were
also detected, findings which were paradoxical because greater
plasma cholesterol concentrations typically lead to larger lesions.
Of note, however, lesion composition was dramatically altered in a
GLUT1-dependent manner. Lesions in mice lacking myeloid
GLUT1 exhibited a greater degree of necrosis and less collagen
content compared with floxed control mice, critical factors asso-
ciated with lesion instability (118). Advanced lesions may or may
not narrow the arterial lumen but are clinically significant because
complications are more likely to develop (119). For example,
pathological studies suggest that the development of thrombus-
mediated acute coronary events depends principally on the com-
position and vulnerability of a plaque rather than the severity of
stenosis (120).
MF glucose metabolism in atherosclerosis was previously in-
vestigated using a GLUT1 gain-of-function strategy in chimeric
mice. By transplanting Ldlr2/2 mice with MFs overexpressing
GLUT1, Nishizawa et al. (121) reported that increasing MF
glucose metabolism by overexpressing GLUT1 did not affect any
parameter of atherosclerosis, including lesion size or necrotic
area. These results were interesting in light of our previous in vitro
model of GLUT1 overexpression, in which GLUT1-mediated
glucose metabolism was shown to play a key role in promot-
ing MFs to mount a robust, proinflammatory response (11).
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